Safety Assessment of *Salvia officinalis* (Sage)-Derived Ingredients as Used in Cosmetics

Status:	Draft Tentative Report for Panel Review
Release Date:	November 10, 2021
Panel Meeting Date:	December 6 -7, 2021

The Expert Panel for Cosmetic Ingredient Safety members are: Chair, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; David E. Cohen, M.D.; Curtis D. Klaassen, Ph.D.; Daniel C. Liebler, Ph.D.; Lisa A. Peterson, Ph.D.; Ronald C. Shank, Ph.D.; Thomas J. Slaga, Ph.D.; and Paul W. Snyder, D.V.M., Ph.D. The Cosmetic Ingredient Review (CIR) Executive Director is Bart Heldreth, Ph.D. This safety assessment was prepared by Preethi S. Raj, M.Sc., Senior Scientific Analyst/ Writer, CIR.

1620 L Street, NW, Suite 1200 ♢ Washington, DC 20036-4702 ♢ ph 202.331.0651 ♢ fax 202.331.0088 ♢
cirinfo@cir-safety.org

SAFETY ASSESSMENT FLOW CHART

INGREDIENT/FAMILY *Salvia officinalis* (Sage)-Derived Ingredients

MEETING December 2021



Cosmetic Ingredient Review

Commitment & Credibility since 1976

Memorandum

To: Expert Panel for Cosmetic Ingredient Safety Members and Liaisons

From: Preethi S. Raj, M.Sc.
Senior Scientific Analyst/Writer, CIR

Date: November 10, 2021

Subject: Safety Assessment of *Salvia officinalis* (Sage)-Derived Ingredients as Used in Cosmetics

Enclosed is the Draft Tentative Report of the Safety Assessment of *Salvia officinalis* (Sage)-Derived Ingredients as Used in Cosmetics (identified as *report_Sage_122021* in the pdf). This is the second time the Panel is seeing a safety assessment of these 12 cosmetic ingredients.

The Panel reviewed these ingredients for the first time at the March 2021 meeting, after which an Insufficient Data Announcement (IDA) was issued. The IDA included all possible data categories for the ingredient group, as well as method of manufacture information for Salvia Officinalis (Leaf) Extract and 28-d dermal toxicity data for both the Salvia Officinalis (Sage) Leaf Extract and Salvia Officinalis (Sage) Root Extract ingredients; if these ingredients were found to be absorbed, additional toxicological endpoints were to be sought.

Since the March 2021 meeting, the following data were received and have been incorporated in the report:

data1_Sage_122021

- Solabia. (2009) Specifications data for a Salvia Officinalis (Sage) Leaf Water
- Solabia. (2009) Specifications data for a Salvia Officinalis (Sage) Leaf Extract

data2_Sage_122021

- Anonymous. (2000). HRIPT of a body lotion containing 0.03% Salvia Officinalis (Sage) Oil
- Anonymous. (2017). Clinical HRIPT of a product containing 0.005% Salvia Officinalis (Sage) Leaf Extract

Of note to the Panel, at the last meeting the placement of data included from an ECHA dossier, which generically applies to most of the ingredients (CAS No. 84082-79-1), was discussed. Although described as a *Salvia officinalis* extract (or even oil), the definition was very broad, and could possibly refer to the water fraction which results from the steam distillation of *Salvia officinalis* to produce oil. Hence, we had placed this data under the Salvia Officinalis Flower/Leaf/Stem Water ingredient heading, and it was agreed that more information on methods of manufacture, and the plant parts used in these methods, were needed to correctly classify this data.

Does the Panel feel that the ECHA data should be moved under other ingredient headings, or can it remain as is?

Also included in this package, for your review, are a flow chart (*flow_Sage_122021*), literature search strategy (*search_Sage_122021*), ingredient data profile (*dataprofile_Sage_122021*), transcripts from the previous meeting (*transcripts_Sage*_122021), ingredient history (*history_Sage_122021*), and 2021 FDA VCRP data (*VCRP_Sage_122021*).

The Panel should carefully consider and discuss the data (or lack thereof), and the draft Abstract and draft Discussion presented in this report. A Tentative Report with a safe as used, safe with qualifications, insufficient, or unsafe conclusion should then be issued.

1620 L Street, NW Suite 1200, Washington, DC 20036
(Main) 202-331-0651 (Fax) 202-331-0088
(email) cirinfo@cir-safety.org (website) www.cir-safety.org

CIR History of:

Salvia officinalis (Sage)-Derived Ingredients

January 2020

-FDA frequency of use data obtained

February and October 2020

-Concentration of use data submitted by Council for most ingredients (Feb) and the Leaf Oil (Oct)

November 2020

- SLR posted on the CIR website

Data received (Salvia Officinalis (Sage) Leaf Extract):

- December 10, 2020: Salvia Officinalis (Sage) Leaf Extract (method of manufacture, impurities and specifications)
- January 5, 2021: Summary Information for Salvia Officinalis (Sage) Leaf Extract. (method of manufacture, composition, impurities, and summary acute toxicity, genotoxicity, and dermal irritation)

January 2021

New VCRP data were received

March 2021

A Draft Report was presented to the Panel at the March meeting. An IDA was issued for the following data needs:
For all ingredients:
• Composition and impurities data, and dermal irritation and sensitization data, at the maximum concentration of use

For the Salvia Officinalis (Sage) Leaf Extract:
• 28-d dermal toxicity data (if absorbed, other toxicological & genotoxicity endpoints for systemic toxicity)

For the Salvia Officinalis (Sage) Root Extract:
• Method of manufacture and 28-d dermal toxicity data (if absorbed, other toxicological & genotoxicity endpoints for systemic toxicity)

Data received (Salvia Officinalis (Sage) Leaf Extract, Leaf Water, and Oil):

- April 1, 2021: Specifications for Salvia Officinalis (Sage) Leaf Extract and Salvia Officinalis (Sage) Leaf Water
- April 29, 2021: HRIPTs for products containing 0.03% Salvia Officinalis (Sage) Oil and 0.005% Salvia Officinalis (Sage) Leaf Extract

December 2021

A Draft Tentative Report is being presented to the Panel.

Salvia officinalis (Sage)-Derived Ingredients Data Profile* – December 6-7th, 2021 – Writer, Preethi Raj																														
				Toxicokinetics			Acute Tox			Repeated Dose Tox			DART		Genotox		Carci		Dermal Irritation			Dermal Sensitization				Ocular Irritation		Clinical Studies	
	Reported Use	Method of Mfg	Impurities	log P/log K_{ow}	Dermal Penetration	ADME	Dermal	Oral	Inhalation	Dermal	Oral	Inhalation	Dermal	Oral	In Vitro	In Vivo	Dermal	Oral	In Vitro	Animal	Human	In Vitro	Animal	Human	Phototoxicity	In Vitro	Animal	Retrospective/ Multicenter	Case Reports
Salvia Officinalis (Sage) Extract	X	X						X						X																X
Salvia Officinalis (Sage) Flower/Leaf/Stem Extract		X												X																
Salvia Officinalis (Sage) Flower/Leaf/Stem Juice		X																												
Salvia Officinalis (Sage) Flower/Leaf/Stem Water		X						X							X				X							X			
Salvia Officinalis (Sage) Leaf	X	X																												
Salvia Officinalis (Sage) Leaf Extract	X	X	X				X								X					X				X						
Salvia Officinalis (Sage) Leaf Oil	X	X					X	X			X									X	X			X						
Salvia Officinalis (Sage) Leaf Powder		X																												
Salvia Officinalis (Sage) Leaf Water	X	X																												
Salvia Officinalis (Sage) Oil	X	X					X	X			X			X	X					X	X			X						X
Salvia Officinalis (Sage) Root Extract		X																												
Salvia Officinalis (Sage) Water	X	X																												

* "X" indicates that data were available in a category for the ingredient

Salvia officinalis (Sage)– Derived Ingredients (12 ingredients- December 6-7, 2021 Panel Meeting)

Ingredient	CAS #	InfoB	PubMed	TOXNET	FDA	EU	ECHA	IUCLID	SIDS	ECETOC	HPVIS	NICNAS	NTIS	NTP	WHO	FAO	NIOSH	FEMA	Web
Salvia Officinalis (Sage) Leaf Extract	84082-79-1	✓	✓	✓	✓	✓*	✓	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	
Salvia Officinalis (Sage) Extract	84082-79-1	✓	✓	✓	✓	✓*	✓	✓*	NR	NR	NR	NR	NR	✓*	NR	NR	NR	NR	
Salvia Officinalis (Sage) Flower/Leaf/Stem Extract	84082-79-1	✓	✓	✓	NR	✓*	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	
Salvia Officinalis (Sage) Flower/Leaf/Stem Juice	84082-79-1	✓	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	
Salvia Officinalis (Sage) Flower/Leaf/Stem Water	84082-79-1	✓	NR	✓	NR	✓*	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	
Salvia Officinalis (Sage) Leaf	84082-79-1	✓	✓	✓	NR	✓*	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	
Salvia Officinalis (Sage) Leaf Oil	8022-56-8 84776-73-8	✓	✓	✓	NR	✓*	✓*	NR	NR	NR	✓*	NR	NR	NR	NR	NR	NR	✓*	
Salvia Officinalis (Sage) Leaf Powder	84082-79-1	✓	NR	NR	NR	✓*	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	
Salvia Officinalis (Sage) Leaf Water	84082-79-1	✓	NR	✓	NR	✓*	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	
Salvia Officinalis (Sage) Oil	8022-56-8	✓	✓	✓	✓	✓*	✓*	NR	NR	NR	✓*	NR	NR	NR	NR	NR	NR	✓*	
Salvia Officinalis (Sage) Root Extract	84082-79-1	✓	NR	NR	NR	✓*	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	
Salvia Officinalis (Sage) Water	84082-79-1	✓	NR	✓	NR	✓*	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	

Botanical and/or Fragrance Websites (if applicable)

Ingredient	CAS #	Dr. Duke's	Taxonomy	GRIN	Sigma-Aldrich	IFRA	RIFM
Salvia Officinalis (Sage) Leaf Extract	84082-79-1	✓	NR	NR	NR	NR	NR
Salvia Officinalis (Sage) Extract	84082-79-1	✓	NR	NR	NR	NR	NR
Salvia Officinalis (Sage) Flower/Leaf/Stem Extract	84082-79-1	✓	NR	NR	NR	NR	NR
Salvia Officinalis (Sage) Flower/Leaf/Stem Juice	84082-79-1	NR	NR	NR	NR	NR	NR
Salvia Officinalis (Sage) Flower/Leaf/Stem Water	84082-79-1	NR	NR	NR	NR	NR	NR
Salvia Officinalis (Sage) Leaf	84082-79-1	✓	NR	#32950	NR	NR	NR
Salvia Officinalis (Sage) Leaf Oil	8022-56-8 84776-73-8	✓	NR	NR	NR	NR	NR
Salvia Officinalis (Sage) Leaf Powder	84082-79-1	NR	NR	NR	NR	NR	NR
Salvia Officinalis (Sage) Leaf Water	84082-79-1	NR	NR	NR	NR	NR	NR
Salvia Officinalis (Sage) Oil	8022-56-8	✓	NR	NR	✓	NR	NR
Salvia Officinalis (Sage) Root Extract	84082-79-1	✓	NR	NR	NR	NR	NR
Salvia Officinalis (Sage) Water	84082-79-1	NR	NR	NR	NR	NR	NR

✓- found in database, or, data was available

✓*- found in database, but data was either irrelevant or not accessible

NR – not reported

Search Strategy

[*document search strategy used for PubMed and/or Toxnet]:* - [*total # of hits/ #hits that were useful*]
Salvia officinalis – 779
(((((salvia officinalis) OR (sage)) OR (84082-79-1)) OR (8022-56-8)) OR (84776-73-8)) AND (toxicity) – 4900/308
(salvia officinalis) OR (sage) OR (8022-56-8) OR (salvia officinalis leaf extract) OR (salvia officinalis extract) OR (salvia officinalis flower extract) OR (salvia officinalis leaf extract) OR (salvia officinalis stem extract) OR (salvia officinalis flower juice) OR (salvia officinalis leaf juice) OR (salvia officinalis stem juice) OR (salvia officinalis flower water) OR (salvia officinalis leaf water) OR (salvia officinalis stem water) OR (salvia officinalis leaf) OR (salvia officinalis leaf powder) OR (salvia officinalis leaf water) OR (salvia officinalis leaf oil) OR (salvia officinalis oil) OR (salvia officinalis root extract) OR (salvia officinalis water):
AND (method of manufacture) – 43/1
AND (impurities) – 5/0; salvia officinalis pesticide – 240/0
AND (dermal penetration) – 1/1
AND (toxicokinetics; pharmacokinetics) – 184/0
AND (acute toxicity) – 34/2
AND (subacute toxicity) – 3/0
AND (chronic toxicity) – 22/0
AND (inhalation toxicity) – 4/0
AND (dermal toxicity) - 1/0
AND (oral toxicity) – 30/0
AND (reproductive toxicity) – 4/1
AND (teratogenicity)- 8/1
AND (genotoxicity) – 21/3
AND (carcinogenicity) – 50/2
AND (mutagenicity)- 54/4
AND (endocrine effects)- 47/1
AND (pigmentation) – 51/0
AND (dermal irritation and sensitization) – 0/0
AND (ocular irritation) – 0/0
AND (mucous membrane irritation) – 0/0
AND (clinical trials) – 485/5
Salvia officinalis leaf extract – 100/3; Salvia officinalis extract- 414/10 ;Salvia officinalis flower extract – 13/2; Salvia officinalis stem extract – 8/0; Salvia officinalis flower juice- 0/0; Salvia officinalis flower/leaf/stem juice – 0/0; Salvia officinalis flower/leaf/stem water- 35/12; Salvia offiicinalis leaf -161/20' Salvia officinalis leaf powder – 2/0; Salvia officinalis leaf oil – 41/12; Salvia officinalis oil - 172/25 ; Salvia officinalis root extract- 22/3; Salvia officinalis water – 23/105

General Web Search
Pharmacokinetics sage salvia officinalis – 41,300/30

Updated search on 10/20/2021:
((((((((((((((((((((((((((((((((((((salvia officinalis extract) OR (sage extract)) OR (salvia extract)) OR (84082-79-1)) OR (salvia officinalis flower extract)) OR (sage flower extract)) OR (salvia officinalis leaf extract)) OR (sage leaf extract)) OR (salvia officinalis stem extract)) OR (sage stem extract)) OR (salvia officinalis flower juice)) OR (sage flower juice))) OR (salvia officinalis leaf juice)) OR (sage leaf juice)) OR (salvia officinalis stem juice)) OR (sage stem juice)) OR (salvia officinalis flower water)) OR (sage flower water)) OR (salvia officinalis leaf water)) OR (sage leaf water)) OR (salvia officinalis stem water)) OR (sage stem water)) OR (salvia officinalis leaf)) OR (sage leaf)) OR (salvia officinalis leaf powder)) OR (sage leaf powder)) OR (salvia officinalis oil)) OR (sage oil)) OR (8022-56-8)) OR (salvia officinalis root extract)) OR (sage root extract)) OR (sage root)) OR (salvia officinalis water)) OR (sage water)) OR (salvia officinalis leaf oil)) OR (sage leaf oil) – 1890/4

LINKS

Search Engines

- Pubmed (- http://www.ncbi.nlm.nih.gov/pubmed)
- Toxnet (https://toxnet.nlm.nih.gov/); (includes Toxline; HSDB; ChemIDPlus; DART; IRIS; CCRIS; CPDB; GENE-TOX)
- Connected Papers (www.connectedpapers.com)

appropriate qualifiers are used as necessary
search results are reviewed to identify relevant documents

Pertinent Websites

- wINCI - http://webdictionary.personalcarecouncil.org

- FDA databases http://www.ecfr.gov/cgi-bin/ECFR?page=browse
- FDA search databases: http://www.fda.gov/ForIndustry/FDABasicsforIndustry/ucm234631.htm;,
- EAFUS: http://www.accessdata.fda.gov/scripts/fcn/fcnnavigation.cfm?rpt=eafuslisting&displayall=true
- GRAS listing: http://www.fda.gov/food/ingredientspackaginglabeling/gras/default.htm
- SCOGS database: http://www.fda.gov/food/ingredientspackaginglabeling/gras/scogs/ucm2006852.htm
- Indirect Food Additives: http://www.accessdata.fda.gov/scripts/fdcc/?set=IndirectAdditives
- Drug Approvals and Database: http://www.fda.gov/Drugs/InformationOnDrugs/default.htm
- http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/UCM135688.pdf
- FDA Orange Book: https://www.fda.gov/Drugs/InformationOnDrugs/ucm129662.htm
- OTC ingredient list: https://www.fda.gov/downloads/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm135688.pdf
- (inactive ingredients approved for drugs: http://www.accessdata.fda.gov/scripts/cder/iig/
- HPVIS (EPA High-Production Volume Info Systems) - https://iaspub.epa.gov/oppthpv/public_search.html_page
- NIOSH (National Institute for Occupational Safety and Health) - http://www.cdc.gov/niosh/
- NTIS (National Technical Information Service) - http://www.ntis.gov/
- NTP (National Toxicology Program) - http://ntp.niehs.nih.gov/
- Office of Dietary Supplements https://ods.od.nih.gov/
- FEMA (Flavor & Extract Manufacturers Association) - http://www.femaflavor.org/search/apachesolr_search/
- EU CosIng database: http://ec.europa.eu/growth/tools-databases/cosing/
- ECHA (European Chemicals Agency – REACH dossiers) – http://echa.europa.eu/information-on-chemicals;jsessionid=A978100B4E4CC39C78C93A851EB3E3C7.live1
- ECETOC (European Centre for Ecotoxicology and Toxicology of Chemicals) - http://www.ecetoc.org
- European Medicines Agency (EMA) - http://www.ema.europa.eu/ema/
- IUCLID (International Uniform Chemical Information Database) - https://iuclid6.echa.europa.eu/search
- OECD SIDS (Organisation for Economic Co-operation and Development Screening Info Data Sets)- http://webnet.oecd.org/hpv/ui/Search.aspx
- SCCS (Scientific Committee for Consumer Safety) opinions: http://ec.europa.eu/health/scientific_committees/consumer_safety/opinions/index_en.htm
- NICNAS (Australian National Industrial Chemical Notification and Assessment Scheme)- https://www.nicnas.gov.au/
- International Programme on Chemical Safety http://www.inchem.org/
- FAO (Food and Agriculture Organization of the United Nations) - http://www.fao.org/food/food-safety-quality/scientific-advice/jecfa/jecfa-additives/en/
- WHO (World Health Organization) technical reports - http://www.who.int/biologicals/technical_report_series/en/
- www.google.com - a general Google search should be performed for additional background information, to identify references that are available, and for other general information

Botanical Websites, if applicable

- Dr. Duke's - https://phytochem.nal.usda.gov/phytochem/search
- Taxonomy database - http://www.ncbi.nlm.nih.gov/taxonomy
- GRIN (U.S. National Plant Germplasm System) - https://npgsweb.ars-grin.gov/gringlobal/taxon/taxonomysimple.aspx
- Sigma Aldrich plant profiler- http://www.sigmaaldrich.com/life-science/nutrition-research/learning-center/plant-profiler.html
- American Herbal Products Association Botanical Safety Handbook (database) - http://www.ahpa.org/Resources/BotanicalSafetyHandbook.aspx
- European Medicines Agency Herbal Medicines - http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/herbal_search.jsp
- National Agricultural Library NAL Catalog (AGRICOLA) https://agricola.nal.usda.gov/
- The Seasoning and Spice Association List of Culinary Herbs and Spices
- http://www.seasoningandspice.org.uk/ssa/background_culinary-herbs-spices.aspx

Fragrance Websites, if applicable

- IFRA (International Fragrance Association) – http://www.ifraorg.org/
- Research Institute for Fragrance Materials (RIFM)

MARCH 2021 PANEL MEETING – INITIAL REVIEW/DRAFT REPORT

Belsito Team – March 11, 2021

DR. BELSITO: Okay. Great. Okay. So now sage. This is the first time we're looking at it. We got quite a bit of data, so let's see how that crunches out. So yeah, the first question I have, Preethi, is under "Chemical Properties," and I think Council also brought this up for the flower/leaf/stem water. You say that essential oil obtained from leaves, flowers, and stalks by steam distillation is a light yellow, dah, dah, dah, dah. And that to me is not leaf water. Water and oil don't mix. I think they maybe get that water during the same distillation process, but the two ingredients are quite different.

MS. RAJ: Yes. Thank you, Dr. Belsito. There was a bit of confusion as to how to classify this ingredient because a lot of this data was taken from an ECHA dossier in which the definition that they had given -- they called it an extractive, which is kind of blanket term for various things. It could be a tincture. It could be an essential oil. It could be -- a ton of these. But then it also kind of -- the way that definition was written it seemed to match closest to the INCI definition for the flower, leaf, and stem water.

So in the Cohen team, we were discussing how definitely the panel would need more clarification on the method of manufacture for these ingredients, which plant parts they're taken from and how they're exactly made because it seems like the water and the oil, which are byproducts of the steam distillation process, could be also derived from a water, as weird as that sounds. So yeah, definitely I think the panel will need more clarification on the method of manufacture.

DR. BELSITO: Yes. Yeah. I think we need, certainly, the method of manufacture for the leaf oil.

DR. LIEBLER: Yeah. I had insufficient for the root and for the flower ingredients for method of manufacture, and composition and impurities for the root, and for comp and impurities for the flower ingredients.

DR. BELSITO: For composition and impurities, I had flower/leaf/stem extract, juice and water, leaf, leaf powder and water, and root extract and water.

MS. RAJ: I'm going to have to get all these again from you, but I do want to also ask the panel Council mentioned reclassifying whatever we had called the flower/leaf/stem water ingredients as the oil ingredients, which there are two. There's a leaf oil, and then there's just an oil ingredient. How does the panel feel about that?

DR. LIEBLER: Well, do you mean renaming them?

MS. RAJ: Yeah. More like correctly classifying them under the oil ingredients as opposed to how it is right now. It says flower/leaf/stem water ingredient. But as you just pointed out, Dr. Belsito, that distinction is not very clear.

DR. LIEBLER: Yeah. I think, Preethi, the names are the names. We're stuck with them. And any imprecision in what the name conveys about the nature of the substance is what we need to resolve. So I agree there could be, from the description that you mentioned, chemical properties -- what says it's a water sounds like an oil. And so we simply need method of manufacture, which I think would be key for that.

And that's why I said the flower ingredients, meaning the flower/leaf/stem, the whatever other has flower in it. Those are all insufficient for composition and impurities. We could just say method of manufacture, composition and impurities and then readdress it next time. And then the root, of course, we got pretty much nothing. I think we're probably okay on the leaf and then the sage extract, which I believe is the whole plant or the leaves.

MS. RAJ: Yeah.

DR. LIEBLER: Don, you mentioned leaf as being a problem, but it looks like we've got pretty good method of manufacture on leaf-containing things. And then composition and impurities, that's our strong suite on the leaf, either the oils and the leaf extract.

DR. BELSITO: No. For manufacture, I just said sage leaf oil. But are you fine with the idea of we have sage oil? We --

DR. LIEBLER: Yeah. That's what I was looking to, Don. The sage oil, it's going to be mainly leaves.

DR. BELSITO: Okay. So, then we don't need that for method of manufacture. And for impurities, I had the flower/leaf/stem extract, juice, and water from those parts. And for leaf, I had leaf powder and leaf water. And for root, I had root extract and root water. But you don't think we need them except for root? You're happy with --

DR. LIEBLER: Yeah. Because I think leaf extract and leaf oil kind of covers the basis for -- and the sage oil kind of covers the basis for the leaf-containing ingredients.

DR. BELSITO: Okay. And covers the basis for the flower/leaf/stem ingredients?

DR. LIEBLER: No. Anything with flower in it is still insufficient for composition and impurities.

DR. BELSITO: And root.

DR. LIEBLER: And the root, correct.

DR. BELSITO: Okay.

DR. LIEBLER: I think we're probably pretty close to where the Cohen team is as well, sounds like.

DR. BELSITO: So, the reason for not asking for all components, the leaf, leaf powder, and water is what, Dan?

DR. LIEBLER: Well, I think we've actually pretty good descriptions of the leaf extract and leaf oil. And then the sage oil, sage being the whole extract and plant, sage extract would be -- I'm presuming whole plant which is mainly leaves.

DR. BELSITO: Okay. So, do we need it for the flower/leaf/stem extract?

DR. LIEBLER: Yeah. Anything with flower in it I came to the conclusion was inadequate.

DR. BELSITO: Okay. So, we need composition/impurities for flower/leaf/stem extract, flower/leaf/stem juice, flower/leaf/stem water, root extract, and root water. Is that what you're saying?

DR. LIEBLER: Yeah. The hitch could come in whether or not the extracts are covered by the oils because we do have Table 2 which has a lot of data on two different leaf oils -- has the two different sage oils, essentially.

DR. BELSITO: Uh-huh.

DR. LIEBLER: And, so, Table 2 is pretty good. And I think the only question is whether the other team feels that we can cover the extract with the oil data. And it really depends on how the extract is prepared.

DR. BELSITO: Okay. But we have information on the leaf extract.

DR. LIEBLER: Right.

DR. BELSITO: Right. Okay.

DR. LIEBLER: Go back up to this method of manufacture for the -- let's see -- the leaf extract, yeah, these are hydroalcoholic extracts.

DR. BELSITO: We have it for the flower/leaf/stem extract.

DR. SNYDER: Dan, can you look on PDF page 12 at the top, the sage oil? It says it was prepared by drying and grinding aerial parts of the plant. So, would that not include everything other than the root?

DR. LIEBLER: Yeah. It would include everything, right. And in fact, the table with the definitions indicates it's the whole plant.

DR. SNYDER: Because we have an eight-week tox study where the NOAEL was 250 milligrams per kilogram per day. So, there's nothing really can be going on in there with anything that's above ground, right?

DR. LIEBLER: Yeah. I think we're reasonably covered with whole plant and leaf for method of manufacture, composition, and impurities.

DR. BELSITO: Okay. But we have good, really detailed manufacturing for the extract. So, I guess you'd be concerned about residual methanol?

DR. LIEBLER: No.

DR. BELSITO: Then what are we looking for in terms of an impurity?

DR. LIEBLER: Right. Method of manufacture, we've got. Impurities --

DR. SNYDER: I think we were okay for everything but the root.

DR. LIEBLER: Yeah. The flower is okay for method of manufacture, but we really don't have anything on composition and impurities for the flower -- for the flower-related ingredients. So, PDF 12 under "Composition/Impurities," you got the sage extract, sage leaf extract, sage leaf oil, sage oil, nothing flower related, nothing root related.

DR. SNYDER: But according to the method of manufacture of the sage oil, that would include the flower, right?

DR. LIEBLER: Well, most of the sage isn't flower, most of it is leaf. So, there might be a little flower in it.

DR. BELSITO: Okay.

DR. LIEBLER: You know what I'm saying, Paul?

DR. SNYDER: Yeah. I do, yeah.

DR. LIEBLER: Okay.

DR. BELSITO: So, we need composition and impurities for the flower/leaf/stem extract, juice and water, and the root extract and water.

DR. LIEBLER: Right.

DR. BELSITO: That's where we're at?

DR. LIEBLER: Right.

DR. BELSITO: Okay.

DR. LIEBLER: Right. Now if somebody could provide us the -- well, no. I won't complicate it any further. Yes. That's right. We need those.

DR. BELSITO: So, then we don't have any absorption data and metabolism distribution, and we have very little DART data. But obviously, the levels are quite high. They are suggesting some effects. So, do we need either a 28-day dermal on those that aren't GRAS -- because several of these are GRAS, right? We just don't really know what parts. I would presume it's the leaf?

DR. LIEBLER: Right.

MS. EISENMANN: Perhaps -- I mean, this is a sage that you use for Thanksgiving.

DR. LIEBLER: Right.

DR. BELSITO: Right. That's what I'm saying. But --

MS. EISENMANN: It's food.

DR. BELSITO: -- that it's derived from the leaf.

DR. SNYDER: Well, it's stem, too.

DR. LIEBLER: Right.

DR. BELSITO: Okay.

DR. LIEBLER: And, Carol, that means it's only a once-a-year exposure.

MS. EISENMANN: No. I use it a lot more than that.

DR. LIEBLER: Sausage.

DR. BELSITO: Okay. So then do we need -- what I'm saying is do we need absorption data for the root? Do we need it for the flower?

DR. LIEBLER: Absorption doesn't really tell us anything with botanicals.

DR. BELSITO: Okay. So, a 28-day dermal?

DR. LIEBLER: Yeah. We could do a 28-day dermal.

DR. BELSITO: At the highest concentration of use?

DR. LIEBLER: Yeah.

DR. SNYDER: Yeah. I had the safe as used other than the root because I figured it was GRAS. We got a 250 milligram per kilogram per day, NOAEL for the sage oil, which is everything above ground. So that's kind of where I was at. But I'll go with the flow.

DR. BELSITO: Okay. So, then we just would need a 28-day dermal for the root?

DR. SNYDER: Yep.

DR. BELSITO: Or the root water?

MS. RAJ: For both the root extract and the water ingredient, Dr. Belsito?

DR. BELSITO: That's what I'm asking.

DR. SNYDER: In the absence of absorption data.

DR. LIEBLER: No. The root extract only. There's just one root ingredient, right?

DR. SNYDER: Yes.

DR. LIEBLER: That's all we need it for, just the root.

MS. RAJ: Okay. Thank you.

DR. BELSITO: You need 28-day dermal for the root extract or absorption. No. You said not absorption.

DR. LIEBLER: Right. 28 day --

DR. BELSITO: 28 day dermal if absorbed --

DR. LIEBLER: Just go right to the dermal because there's no absorption data that we could get that we would find useful because it's a botanical. It's so complex.

DR. SNYDER: Right.

DR. BELSITO: Right. So, we need a 28-day dermal for the root extract and if positive?

DR. SNYDER: Yeah. If absorbed, then systemic toxicity, yeah -- other endpoints.

DR. BELSITO: Okay. Other data may be necessary or other endpoints?

DR. SNYDER: May be necessary, yes.

DR. LIEBLER: The 28-day dermal is just a toxicity study, right?

DR. SNYDER: Correct.

DR. LIEBLER: Yeah. So, if that's negative, then we're done with that.

DR. SNYDER: Probably not going to get it because it's not used.

DR. LIEBLER: Right. Of course.

DR. BELSITO: Okay.

DR. SNYDER: And we did get some comments, Don. Did we need to talk about those or not?

MS. RAJ: I do have a question. Also, there was no data for the leaf powder ingredient, but -- oh. I guess that comes under the leaf ingredients. So, I guess that's fine?

DR. BELSITO: Okay. So that in terms of the DART data, Paul, we just get rid of that by the very high doses, okay? Is that right?

DR. SNYDER: Yes. Again, it's not really a DART study, anyway. It was the developed mammary gland over the estrous cycle.

DR. BELSITO: Okay. What about the genotox? We're okay with that except, again, like that would be another endpoint for the root. Is that correct? I would also point out that we don't have any mammalian for flower/leaf/stem water and the flower and the leaf extract.

DR. SNYDER: I wasn't concerned with it being GRAS but --

DR. BELSITO: Okay. I mean, is --

DR. SNYDER: Yep. I understand.

DR. BELSITO: So, we're just going with saying nothing about genotox just -- at this point?

DR. SNYDER: Yeah.

DR. BELSITO: Okay. So, the only one that --

DR. SNYDER: We're only talking 0.38 percent is the maximum for the -- I don't remember which one it was. Yeah. The leaf extract was 0.38 percent. That was the maximum concentration of use.

DR. BELSITO: Okay. So, you're comfortable with the information we have on genotox for all of them except the root, and that will then depend on the 28-day dermal. Irritation, we have it only for the leaf extract. And I don't know --

DR. SNYDER: We got it for the -- the oil --

DR. BELSITO: But we don't --

DR. SNYDER: -- is 8 percent oil or leaf oil? One of them.

DR. BELSITO: Yeah. We don't know.

DR. SNYDER: Yeah.

DR. BELSITO: So, where are we? We are --

DR. SNYDER: Well, we got two new HRIPTs in Wave 2.

MS. RAJ: Much lower than the maximum reported concentration of use, though.

DR. SNYDER: Correct. Right, 0.01 and 0.015.

DR. BELSITO: Yeah. I had we need all except for the leaf oil for sensitization. And then the question, could the oil be used to read across from the leaf oil? Oh, we didn't know. Well --

DR. SNYDER: Right. We don't know which it is.

DR. BELSITO: -- I guess, my question was, wherever this oil is extracted from, can it substitute for sage or sage leaf oil? Because I don't think there's going to be a lot of oil in the root -- or in the stem, rather -- but maybe I'm wrong. Aren't you going to find most of the oil in a leaf? What do you think, Dan?

DR. LIEBLER: Yeah. I think so.

DR. SNYDER: If you look on page 19 and go down to composition of the leaf oil versus the oil, is there anything there that would concern you for sensitization?

DR. LIEBLER: I'm scrolling.

DR. BELSITO: Yeah. Well, you got that huge gap in thujone, not as sensitizer, but it has its own toxicity. But it'll be very low by the final formulation. Camphor, not really much of a sensitizer. Borneol, not really much of a sensitizer. And, again, the concentrations are going to end up being very low. Caryophylene, no. I think the -- I mean, not really, Paul.

DR. SNYDER: Yeah. I didn't think so either. And so irrespective, we have an 8 percent whatever oil it is. With 25 it was negative. And then we got those lower ones.

DR. BELSITO: Yeah. But I guess the question I have is can the oil -- so the oil -- I think the oil can cover the leaf. But I don't know if it can cover other parts. And then the question is can it cover a leaf extract? But it's not likely that they would contain more sensitizers than the oil.

DR. LIEBLER: The oil is going to sort of supreme in concentration of sensitizers because it's mostly those terpenes.

DR. BELSITO: So, what do we need in terms of sensitization? And what do we need in terms of irritation? Really, the only information that we have about composition is on the oil, correct? And the sensitization data that we have -- I don't know why it's not going back to the page.

DR. LIEBLER: My take is that the oil is going to have the highest concentrations of substances of concern for sensitization, the terpenes.

DR. BELSITO: Okay.

DR. LIEBLER: And so sage oil or sage leaf oil should suffice for that purpose if you're going to prioritize what to do sensitization on because you clearly -- you got this maximization test on 25 subjects. I don't know how satisfactory that is. It's up to you and David to -- and we'll want to talk about -- but if you're going to prioritize something for sensitization data, I would think it's the oil, either the sage oil or the leaf oil or both.

DR. BELSITO: I would agree. So, we got a human max 8 percent in petrolatum, no sensitization. A small number of subjects, but it's supported by the lack of --

DR. LIEBLER: Composition issues.

DR. BELSITO: -- well, and also the lack of clinical studies. You're talking about a botanical. You're talking about a plant that people handle. It's been ground up if they're cooking and rubbing sage onto whatever. And we've got two reports, one of a sage extract and one of a sage oil. So, I think the oil would have the highest component of sensitizers, and the lack of clinical data suggests that sensitization is not an issue in cosmetic products. Is that fair?

DR. SNYDER: Yeah.

DR. LIEBLER: Yeah.

DR. BELSITO: And irritation? I mean, we have an in vitro.

DR. SNYDER: I didn't think it has an irritant.

DR. BELSITO: Yeah. I certainly didn't see anything in the oil that looked irritating, but that's all we have composition on. And I'm just looking. The highest leave-on use 0.38 for the leaf extract? Is that right? Then we have irritation data (audio skip) on the leaf extract undiluted at 10 percent --

MS. RAJ: Sorry, excuse me. If we were to reclassify the flower, leaf, and stem water as an oil ingredient, that would leave us with irritation and, I guess, sensitization data only on the oil ingredients.

DR. BELSITO: No. I think we're not --

DR. SNYDER: No. I think we're good on those.

DR. BELSITO: We're not reclassifying the water as an oil.

DR. LIEBLER: Yeah.

DR. BELSITO: We think that steam distillation -- they take one fraction which has gone up in the steam, and that's the water extract. And then what's left is the oil extract.

DR. LIEBLER: I think what happens, for what it's worth, is that the steam contains aqueous and oil-like components. Once they're condensed and they collect in a little vial or a bottle, the aqueous goes to the bottom and the oil comes to the top. I remember literally seeing that, Don, when we took the tour --

DR. BELSITO: Oh, yeah. That's right, in GRAS.

DR. LIEBLER: Yeah. When they were doing the iris root, remember that?

DR. BELSITO: Yeah. And then they skim it, and then they further purify it.

DR. LIEBLER: Right. But I think the Council memo makes the point very well about the difference between a water and an essential oil. And I think calling it an essential oil is probably a misnomer, even if somebody else used that term. And unless we have a better description that makes it clearer what's the aqueous component, what's the oil component, we should stick with the water being more like a water and not an oil.

DR. EISENMANN: Yeah. But we're talking about all the studies that came from the ECHA dossier were on an oil. And I think they are not -- they're in the report as water. So, I looked at the dossier, and the way they describe the material that they're supporting is as an oil. (Audio skip) call it sage oil. So, all those studies should be as an oil, not as the water.

DR. LIEBLER: Yeah. But Carol, can't --

DR. EISENMANN: So, yes, there's a difference, but the studies from the dossier are on an oil. And I think that's the main material of commerce anyway.

DR. LIEBLER: Carol, can we associate what's in the ECHA document with a high degree of confidence with a cosmetic ingredient?

DR. EISENMANN: I would assume so because they're providing that material that they have to be doing what's in commerce.

DR. LIEBLER: Right.

DR. EISENMANN: I have to look again and see if any of the suppliers are the same as what we have listed.

DR. LIEBLER: Let me rephrase my question. Which cosmetic ingredient in our list could the ECHA data be associated with?

DR. EISENMANN: That is the issue. I'm not sure if it's the oil, which would be like the whole plant or the above-ground oil or just the leaf.

DR. LIEBLER: Okay. That's what we need to know.

DR. EISENMANN: I can't tell that. But I believe it's an oil and not a water --

DR. LIEBLER: Yeah.

DR. EISENMANN: -- based on what I read.

DR. BELSITO: Okay. But for the leaf -- so first of all, flower/leaf/stem, a major component would be leaf, right?

DR. LIEBLER: I think so.

DR. BELSITO: Right. And the oil would be largely derived from the leaf. And, so, if the oil is safe, then (audio skip). And given the highest concentration of use at 0.57, I'm not sure why we're having problems with the other above-ground components. I agree with the root but --

DR. LIEBLER: I'm not sure either.

DR. BELSITO: Paul, Curt?

DR. SNYDER: I didn't have an issue.

DR. KLAASSEN: Yeah. I'm not concerned.

DR. BELSITO: Okay. So, we're going insufficient for the root components for a 28-day dermal and (audio skip) necessary and safe as used for all the others?

DR. SNYDER: That's what I have.

DR. BELSITO: Okay. And in the discussion, Preethi, we obviously need the usual plant and inhalation boilerplate and the fact that the sage leaf and presumably stem are GRAS components and would be the major component of the flower/leaf/stem extract, juice and water -- the leaves would contribute the greatest amount to those. And, so, we felt that the -- and that the oil would contain the major sensitizers and that mitigated the need for sensitization data on the other ingredients except for the root.

DR. SNYDER: We don't have a maximum concentration of use for the root because it's not used.

DR. BELSITO: So, we probably won't get it, and then we'll just go insufficient, right?

DR. SNYDER: Yeah.

MS. RAJ: So, thank you, Dr. Belsito and everyone. I just want to clarify. Is it a split conclusion, where you are asking for the composition and impurities for all the flower ingredients -- ingredients which contain flower in them, you're asking for composition and impurities? And, also, for the -- is it the extract, the juice, the root extract, and the water ingredient you also want the composition and impurities?

DR. BELSITO: I thought we just said that those were all safe as used.

DR. SNYDER: Yeah. I think we came back around, Preethi.

MS. RAJ: I see. Okay.

DR. SNYDER: So, they're safe as used.

DR. BELSITO: So, basically, the leaf is going to be the major driver for all tox endpoints for the other parts of the plant except the root.

MS. RAJ: Okay. So, you no longer need the method of manufacture and composition/impurities for the flower ingredients because the leaf will drive that. Is that right?

DR. LIEBLER: Right. Correct.

MS. RAJ: Okay. But you still want method of manufacture, composition and impurities for the root extract and a 28-day dermal tox for the root extract?

DR. BELSITO: Right.

DR. SNYDER: And sensitization.

MS. RAJ: And sensitization. And no need for irritation, right, just sensitization?

DR. BELSITO: For root? Yeah.

MS. RAJ: Yeah.

DR. BELSITO: We need sensitization and irritation.

DR. KLAASSEN: Which we'll never get.

MS. RAJ: And, I guess, then it's a split conclusion then because you're going insufficient for the root extract, but then you're safe for all the other things?

MR. HELDRETH: No, Preethi, there's no conclusion. It's a draft report with insufficiencies, so the only thing coming out of this meeting is an IDA.

MS. RAJ: Okay.

MR. HELDRETH: For the root.

MS. RAJ: Yeah. Sorry.

DR. SNYDER: We're sorry. We were very confusing.

DR. LIEBLER: Yeah.

MS. RAJ: Yeah. I'm still trying to get a handle on botanicals, so excuse me.

DR. LIEBLER: Well, I hope you weren't hoping for good sage wisdom from us.

MS. RAJ: That's okay. I think I got a good share of that.

DR. LIEBLER: Yeah. You have another one: papaya.

DR. BELSITO: Yeah. So basically, yeah. So, all of them except the root-derived components are safe as used. And for the root we need manufacture, impurities, 28-day dermal, and, if absorbed, other systemic endpoints and sensitization and irritation at concentration of use.

DR. SNYDER: Well, I think we could say at the max for -- because we'll say it's used as others, and the max is 0.38.

MS. RAJ: Thank you.

DR. BELSITO: Okay. Anything else on this?

MS. RAJ: I think that's it.

Cohen Team – March 11, 2021

DR. COHEN: Okay. The next item for this very sage team is sage. I'm sorry, I couldn't help myself. This is Preethi's. It's a draft report. This is the first time we're reviewing it.

This safety assessment is for 12 items. It's used as a skin conditioning agent and a fragrance. The leaf extract has the greatest frequency of use. The leaf extract also has the highest reported concentration of use at 0.38 percent. There are formulations that will expose the mucus membranes in bath soaps and detergents and the use of the sage oil at 0.02 percent.

MS. RAJ: Dr. Cohen --

DR. COHEN: Yes.

MS. RAJ: I'm so sorry to interrupt you, but I just realized I wanted to ask the panel one last thing about the levulinic report.

DR. COHEN: Yes, of course.

MS. RAJ: Because we got a comment from Council suggesting that they wanted the outcome of the RIFM assessment to be included as a separate section in a risk assessment part of the report. So, I just wanted to know the panel's thought on that, and what exactly needs to be included in this.

DR. SHANK: We haven't seen that RIFM statement, have we?

MS. RAJ: So, it's an Api (phonetic) et al. report that has been included in the report. But I guess Council thought that there needs to be a separate risk assessment section in that report. And the outcome of that assessment needs to be included in there. But to me, that seemed a little vague. I wasn't really sure what they wanted in there.

DR. SHANK: Maybe Alex could explain that to us.

DR. BERGFELD: Or Jay.

DR. SHANK: Jay.

DR. ANSELL: Yeah. We just thought that the RIFM analysis included tox data endpoints which were relevant to this discussion. But since we feel that in aggregate the tox questions are addressed, I think just making sure that it's identified in the discussion would be sufficient.

MS. RAJ: So sorry, Jay, am I hearing we wouldn't need a separate risk assessment section then? You just want it to be mentioned in the discussion?

DR. ANSELL: We want to make sure that people are aware of the data that RIFM identified that would be relevant. It's a food additive use and human studies.

MS. RAJ: Okay.

DR. COHEN: So, this would appear in the discussion, and since this is a tentative report, we'll see it before we finally approve it, right?

DR. ANSELL: Yes.

MS. RAJ: Okay. Thank you.

DR. COHEN: Okay. Back to sage. We have the information on leaf extract using pump and aerosol sprays at up to 0.002, and the leaf oil is in suntan formulations. And the flower leaf stem water and sage water are reported to function only as a fragrance, so I'll need your help how we adjudicate that. So, can we cluster all these in here? Can we include all of them and read-across?

DR. SLAGA: I have one question. It was unclear to me that sage extract -- if it's the whole plant, or there's one sentence where it mentions how it's made, that it's related -- it's the leaf. We already have a leaf extract. It doesn't make sense to me. If it's the whole plant then, you know, that gives us more read-across potential. So, does anyone know for sure if it is the whole plant?

DR. COHEN: Well, when you read that, it looks like it's a tiny batch of just leaves. I hardly --

DR. SLAGA: Yeah. That's what it sounds like to me --

DR. COHEN: -- (inaudible) a commercial application with method of manufacturing.

MS. RAJ: Can anyone from wINCI comment?

DR. SHANK: I have another question, Preethi. All of the data, at least the toxicology data for these ingredients --

MS. RAJ: Yes.

DR. SHANK: -- are in italics, which means they're not necessarily cosmetic ingredients. Is that correct? So, we really don't have any toxicology information on --

MS. RAJ: That's correct.

DR. SHANK: -- sage ingredients that we know that they're cosmetic ingredients?

MS. RAJ: Yes. We only received the two HRIPTs that are known cosmetic ingredients. Yes.

DR. SHANK: Right. But the tox data are all sort of generic, I guess.

MS. RAJ: Yes.

DR. SHANK: I'm really not too sure how to handle that. I would like to have some information to help me extrapolate from the data that's in the report, at least the tox data, and how that applies to cosmetic ingredients. So, I guess this is a question for the chemists.

DR. SLAGA: I had the same concern as you, Ron, also, and I didn't know how to deal with that. There's a lot of data, so to speak, in there.

DR. SHANK: Yes. Correct. Now, this is a food or an herb. Yes, an herb.

MS. RAJ: Yeah. Which would make the consumption very less.

DR. PETERSON: Much -- yeah. Very low.

DR. SHANK: Yeah. So, I guess we could rely on that. Yeah. If it's a food, we don't need very much tox data.

DR. SLAGA: Yeah. Also, the sage is put on meats as a flavoring. And, so to say -- the leaf extract, so actually, we have a lot of safety relationships there too, that it's eaten.

DR. ANSELL: The approach we followed in the past, and that we support, is that materials which are food items with a long history of use can use that to resolve the systemic issues that -- because of the processing in a water or an oil, there would be a need to look at topical effects. But the food use would address the systemic issues.

DR. SLAGA: Right. I agree.

DR. SHANK: Okay. I agree also.

DR. COHEN: Well, we had a memo --

DR. PETERSON: So --

DR. COHEN: Oh, go ahead. Go ahead.

DR. PETERSON: The only thing we don't have much information on is the root extract, and I don't --

DR. BERGFELD: Not there.

DR. PETERSON: And I think the --

MS. RAJ: Yeah. It doesn't --

DR. PETERSON: -- the root would be --

DR. SLAGA: Don't have any on the root I don't think.

MS. RAJ: Hmm-mmm.

DR. COHEN: Right. And I have the same thing. We have nothing on the root.

MS. RAJ: And excuse me, I don't know if this is the right moment to bring this up, but Council did also bring up that a lot of this data is coming from an ECHA dossier in which we felt the definition aligned the most with the wINCI definition for salvia officinalis flower, leaf, and stem water. But they, you know, brought to our attention that, you know, there's a difference between the water and the oil. They felt that whatever was described in the ECHA dossier was more relevant or pertinent to the oil ingredients, which would be the leaf oil and the, you know, oil. So, I guess, how does the panel feel about that?

MS. FIUME: And just to add a little bit to that. So, the ECHA dossiers, especially when it comes to botanicals, often they're hard to discern. It'll describe the test product as an extractive, which could be a number of items. It did say a steam distillate. We were basing the fact that the water was a steam distillate.

And, Jay, you can clarify further that the steam distillation could produce a water or an oil. I believe the CAS number may correspond to the oils, so it may be appropriate to put it under the oil for the whole plant. Between Council and the panel's preference or expertise, we will move the data wherever you feel it is most appropriate. But, Jay, if you want to go on a little further about how those are processed and then classified as to the ingredient.

DR. ANSELL: Yeah. I think this is the first round, and so we're going to be quite open to resolve some of these questions. But yeah. I mean, the water and the oil -- the oil is typically made through steam distillation. And, so, we do think that's the most relevant. But we'll take that under advisement and come back with, you know, more detail as we go forward.

MS. FIUME: And this is a point of clarification for the panel then. In instances where in the report currently, there are data for the flower, leaf, steam, water, that will no longer be true. It would most likely be placed under the oil of the whole plant, which would mean, then, there's no tox data for that water ingredient.

DR. COHEN: That's kind of how I read into it, particularly after Bart's memo. It's that we have a lot of data on the oil, but I don't know what that water fraction, you know, may have in it and what data we have on that by trying to extrapolate back. And we already pointed out the method of manufacturing for the sage extract just looks like it's coming from leaves.

MS. FIUME: That may be a placement issue. Reading it again, I wonder if that should be placed under the leaf extract, being that it looks like it's a tea made out of sage leaves, and we can move that. So being that this is the first time, we would have -- I think asking for that in an IDA, and even clarification as to what is in all those plant parts, wouldn't be a bad thing to help the panel really figure out what's what in this report.

DR. COHEN: Yes.

DR. ANSELL: No, I was just also going to point out concerning discussions of roots, we would not extend the food use to plant parts which are not in fact, you know, food items.

DR. SHANK: Right.

DR. SLAGA: Right.

DR. ANSELL: So, focusing typically in these analyses on fruits or stem, fruit, leaf combinations.

DR. COHEN: So, could you guys help me articulate what we're going to ask for tomorrow in our IDA? Do we want impurities and method of manufacturing for root?

DR. PETERSON: Yes.

DR. SLAGA: Yes.

DR. PETERSON: Yeah.

DR. COHEN: And what about relevant tox data since it's --

DR. SLAGA: Irritations, sensitization, and genotox.

MS. RAJ: Preferably at the maximum use of concentration or higher?

DR. SLAGA: Right.

DR. SHANK: We have genotox on the oil.

DR. SLAGA: But not the root.

DR. SHANK: Oh, you were talking just the root.

DR. SLAGA: We're on the root.

DR. COHEN: We're on root now.

DR. SLAGA: Yeah. We're down under the ground.

DR. SHANK: Sorry.

DR. COHEN: We're working our way up. Anything else on root that we want right now?

DR. PETERSON: Did you put composition? So, we have method of manufacturing, composition, and impurities.

DR. COHEN: Yes.

MS. RAJ: So, am I hearing right that you want all this information only for the root ingredient?

DR. PETERSON: We're not --

DR. COHEN: Well, no. We're just on root now.

MS. RAJ: Oh.

DR. SLAGA: Yeah.

MS. RAJ: Okay.

DR. COHEN: We're working our way up to the aerial parts of the plant.

MS. RAJ: Okay.

DR. COHEN: And Wilma, thank you for pointing that out in the introduction how challenging these can be. I felt you were speaking to me.

DR. BERGFELD: Speaking to myself. Oh, my god, wait until you get to red algae.

DR. COHEN: Okay. So now, what about the aerial parts of the plant, and how do we adjudicate the aqueous versus the oil parts? What do we feel we have, and what do we need?

DR. PETERSON: Well, I have gotten all confused now by what is oil and what is water because of the conversation we've just had. But I think we have a lot of information on what's an oil.

DR. SLAGA: Yeah. I think we're okay with oil in terms of needs.

DR. ANSELL: So, it's the method of manufacture, right? Because I do believe that the difference between the oil and water is not the extraction method but rather the final preparation.

DR. SLAGA: Okay.

DR. ANSELL: The oil is actually just the water without the water.

DR. PETERSON: That doesn't make sense why they would call it water when it's oil. Jay, what you're saying is that the water is oil, right?

DR. ANSELL: No.

DR. COHEN: No.

DR. ANSELL: I'm saying, is that they all arise from a water extract, and it's the further processing which would distinguish a water from an oil. Juice would typically be squeezed, but an oil and water would be more of a concentration -- a post-extraction concentration. I think that's a very valid question. And I think it's one that we would take on and give a little more clarity.

DR. PETERSON: Yeah. That would be great because from what you said -- just let me repeat so that I make sure that I understand. So, the water is basically the tea, or whatever, that's used to then do the distillate to get the oil?

DR. ANSELL: That is my understanding.

DR. PETERSON: Okay.

DR. ANSELL: But I do believe that that's a great question. And we will address that for the next report, clarify a method of manufacturing to distinguish them.

DR. COHEN: So, might we get more specific and say flower/leaf/stem water and leaf water, we want method of manufacturing, composition, and impurities?

DR. PETERSON: Yep.

DR. COHEN: And it looks like we need -- do we need tox on it, I think? I don't think we -- oh, we have some.

DR. SLAGA: Dermal irritation, sensitization, and genotox.

MS. RAJ: Well, just --

DR. COHEN: Okay.

MS. RAJ: -- just to remind, once we do the change, or if we move the data to the oil, I don't know how much data we'd have on these water ingredients. We would not have any.

DR. COHEN: So, we'll need dermal tox?

DR. SLAGA: Yes.

MS. RAJ: I think so.

DR. ANSELL: Well, if their --

DR. SLAGA: No.

DR. ANSELL: -- if the only difference is concentration, asking the compositions will -- once diluted in a natural product would end up being the driver and could end up being the same concentration. So, I think it's all going to come more clear once we have the method of manufacture.

DR. COHEN: I guess what's confusing me is, like, okay, you have this distillate and the oil goes to the top presumably. You take that off, there are going to be different components in the aqueous phase than in the oil phase, right?

DR. SLAGA: Right.

DR. COHEN: So, they seem like two different line items entirely.

DR. SLAGA: Right. I agree.

DR. PETERSON: If that's what water is, then yeah. But I'm still confused about what water is, so do have to define that? And then, depending on the method of manufacturing and what the water is, we're going to either need the components or not need the components depending on the method of manufacturing. So, can we specify that if it's this, we need that, or if it's that, we don't need anything at all? Because if it's --

DR. COHEN: Well, why don't we just ask for what we want. And when it comes back, we can fill in the blanks. Because if we do a lot of if/then statements, then it -- we have to give them a cutoff on what we want to see.

DR. PETERSON: Sure. Sure. Sure. And we can go back with another request for data.

DR. ANSELL: Yeah. And I think the question is clearer as opposed to hypothetical answers and then further questions. We would just need to know -- I think we need a distinction of what you're thinking of as an oil would be compressed as opposed to the concentration of the steam distillate. And that would resolve a number of the questions.

DR. BERGFELD: David, I have a question that's a little bit different, and that appears under dermal irritation and sensitization in vitro test. And it's called the RHE, R-H-E test, and the bottom result, it was not a corrosive. I'm not familiar with that particular statement. Not corrosive, do they mean not irritating or truly not corrosive?

MS. RAJ: That's probably how it was written in the source, Dr. Bergfeld. But perhaps that could also mean not irritating.

DR. BERGFELD: I think that's probably what it means.

DR. COHEN: Yeah.

MS. FIUME: And these tests are predictive tests; they're not absolute.

DR. BERGFELD: Yeah.

MS. FIUME: So, the in vitro tests are a prediction that it would not be considered corrosive --

DR. BERGFELD: Well corrosive (audio skip).

MS. FIUME: -- is the terminology they use.

DR. BERGFELD: Yeah. But does that mean irritating, Monice?

MS. FIUME: That's how I would interpret it but --

DR. BERGFELD: Irritation and corrosive are in the same line, one being more severe than the other.

MS. FIUME: I'm not extremely familiar with the toxicology of all of the in vitro tests. But I believe for some of these in vitro tests rather than -- sometimes there's data saying not predicted to be irritating. But predicted not to be corrosive does seem to be common in the conclusions that we get. So, we can only go with whatever wording was in the document that we had in front of us.

DR. COHEN: We don't tend to use that in the medical vernacular very much, corrosive.

DR. PETERSON: Yeah. That sounds like a chemistry lab concern.

DR. COHEN: Now, it looked like we have some sensitization and irritation at 8 percent in humans in the oil. And there were a few cases of allergic contact dermatitis in the lip balm and in aromatherapy oil. And in some late-breaking data that was sent, we have sensitization at 0.01 percent of the leaf extract at 110 subjects, but the max use of the leaf extract was 0.38 percent. So, it didn't satisfy our typical criteria.

And we had a max formulation of 0.015 percent for the oil in 105 subjects, but we have max use of 0.022. So again, we still need that max use -- well, we may not if we have the 8 percent oil. I'm sorry, I just want to make sure I'm covering all of that. We may be okay with oil and irritation and sensitization.

DR. PETERSON: Yeah. I mean, the chemical composition of the oil, it does have a chemical that's irritating and sensitizing. So, I think -- I mean, I have a note that we should have -- that it needs to be formulated not to be sensitizing or irritating. And then there's also a neurotoxicant in it.

And again, I don't think this is a concern when it's food, but if the concentrations are high enough in an oil, and it's used enough, then I guess you would worry about whether it penetrated or not. But, you know, I don't think there's any evidence of problems, but I just wanted -- from a chemist's perspective, there are chemicals in the oil that have some toxicological properties.

MS. FIUME: And David, if it's okay, I'd like to add, I know, Lisa, you had said earlier that we can go back and ask for more. Procedurally, we try and -- or I should say the panel tries to cover everything in the IDA so that we don't have to go back and do a second IDA. As I'm looking at the method of manufacture, it looks like the only information that we have for that, that is known to be a cosmetic ingredient, is on the leaf extract because that information was provided by suppliers. Where the others are general processes that were found in the published literature that we don't know how they necessarily apply to the cosmetic ingredients.

So, I don't know if that helps you as you're formulating your list or not. Because even in the irritation and sensitization part of the paper, I think a lot of that information came from a RIFM document that was done a long time ago on a sage oil.

MS. RAJ: Yes.

MS. FIUME: So, again, a generic name not exactly knowing if it's a one-for-one to what the current cosmetic ingredient is. So, I don't know if that helps you as you're forming your list for the IDA or not, but I did just want to point out those couple of items.

DR. COHEN: I think it does, then. So, are we going to ask for then, irritancy and sensitization on the other components at max use?

DR. SLAGA: Yes.

DR. PETERSON: And then we would want method of manufacturing for the cosmetic industry because I'm -- yeah, I'm still catching on this subtlety between what's okay to use and what's not okay. But it does make sense that it's possible the cosmetic industry is using something different than these references that you found. So then one would say we would need to have method of manufacturing on the items used in cosmetics.

DR. SHANK: I agree with that.

DR. SLAGA: Yeah.

MS. RAJ: Dr. Peterson, I just want to clarify from what you said before. So, does it sound like you would want to point out which of these components are, I guess, potential sensitizers or irritants or whatever? Because I know in our report, we kind of emphasized that we're reviewing these complex mixtures and not individual, you know, constituents --

DR. PETERSON: Right. Right. You have the -- I mean, you had that nice boilerplate sentences that talk about, you know, making sure that the reader understands that the cosmetic ingredient is a mixture and that, while there may be components of it that have some activity, we don't focus on the individual components. We focus on the mixture. And my only point for pointing them out is that, you know, that there's a sensitizer in there means that we have to think about the sensitizing potential of the overall cosmetic ingredient. You know what --

MS. RAJ: Yes.

DR. PETERSON: -- you need that data to, you know, you need to have the data to support that the cosmetic ingredient doesn't have the irritation, or it would have the irritation. And then we have to make a recommendation that anything using that ingredient needs to be formulated -- because the mixture is going into another mixture, and who knows what the interactions are between the chemical. Whether they enhance or -- you know, in some cases they can mute the biological activity of the individual component, depending on what else is in the mixtures.

And we don't really know that, so what we want is the safety information on the mixture. But, you know, to me it's an alert that there's a sensitizer in it, so we have to think about it.

MS. RAJ: Absolutely. And I'm kind of curious, too, because I'm also, you know, learning the world of botanicals. But would you say that perhaps -- I mean, it's hard to know, again, until you see the method of manufacture and, you know, I guess consider which constituents are maybe more prevalent in some ingredients more than others. But would you say as a panel that maybe you would, I guess, be more concerned about some ingredients than others in the group based on the level of these constituents in them?

DR. PETERSON: Yeah. I mean, if it turns out that it's 34 percent, or something like that, then it's a bigger concern than if it's less than 1 percent. You know, so I do think that knowing the composition helps you make your safety assessment, again, with the caveat you don't know how, you know, a lot of the testing of these individual components is done as a pure mixture. And

when you start putting it in a mixture, there's other chemicals in the mixture that can either enhance or diminish the biological activity of the individual component.

MS. RAJ: Thank you.

DR. COHEN: So, just to circle back, we have method of manufacturing for the leaf extract, but we probably don't for anything else, then?

DR. PETERSON: Yep.

DR. COHEN: And, so, do we need the entire repertoire of requests for everything?

DR. SLAGA: The rest.

DR. COHEN: For the rest?

DR. PETERSON: Yep. Yep. And then we can see what we get, and then we can -- based on, you know, further clarification and --

DR. COHEN: All right.

DR. BERGFELD: The problem is just botanicals always is the composition and the impurity then.

MS. RAJ: So, am I hearing for everything besides the leaf extract, you want method of manufacture, composition, impurities, relevant tox data, and dermal irritation and sensitization data?

DR. COHEN: Yes.

DR. SHANK: And make sure that's for cosmetic ingredients.

MS. RAJ: Cosmetic ingredients.

DR. PETERSON: Right.

DR. BERGFELD: Cosmetic grade or ingredients, yeah.

MS. RAJ: Thank you.

DR. COHEN: All right. I'll put that together to articulate tomorrow. Okay.

Full Panel – March 12, 2021

DR. COHEN: Okay, thank you. Sage, it's the first time we're reviewing this. It's used as a skin conditioning agent and a fragrance. And there are 12 derived ingredients. Leaf Extract is reported to have the greatest frequency. Leaf Extract also has the highest reported concentration of use, at .38 percent. And there are formulations that come in contact with the mucus membrane, such as sage oil, at 0.02 percent in bath soaps and detergents.

Our team suggested coming out with an insufficient data announcement. We have a lot of information about the oil component, and in fact it is a food. It's used as a seasoning.

For the aqueous components, we're asking for composition and impurities, dermal tox, genotox, irritation and sensitization at max use, for the Flower/Leaf/Stem/Water, Water and Leaf Water. And, additionally, for the Root, we would need the same things as above including the method of manufacturing since we had nothing for it.

DR. BERGFELD: And that's a motion?

DR. COHEN: That's a motion.

DR. BERGFELD: Is there a second or comment?

DR. BELSITO: We'll second the insufficiency. I'm not sure exactly if our lists match.

DR. BERGFELD: Okay, well, let me make an amendment here. It's going insufficient, and we'll vote on that. And then we'll discuss the needs, okay? Is that all right, David?

DR. COHEN: Yes.

DR. BERGFELD: All right. Any opposed to going insufficient? Abstaining? Hearing none, it's approved. Now, let's discuss the needs. Do you want to compare -- why don't you take one at a time, David, and let Don respond.

DR. COHEN: Okay, so, Don, for Flower/Leaf/Stem/Water composition and impurities, dermal tox, genotox, irritation and sensitization at max use.

DR. BELSITO: So, we asked for a 28-day dermal and if absorbed then those.

DR. COHEN: Okay.

DR. BELSITO: Those are rather extensive test we're getting.

DR. COHEN: Okay. Ron, any concerns with that? Yeah, I think we're fine with that. I would say, we would duplicate that for Water and Leaf Water. And, all of those for Root, including method of manufacturing.

DR. BERGFELD: All right, for clarity again. For the group that you're going to ask for the 28-day dermal, is that the only one to be included there, or you're going to ask for anything else? The Flower/Leaf/Stem --

DR. BELSITO: We need sensitization for all except the Leaf Oil.

DR. COHEN: We agree.

DR. BERGFELD: Okay. So 28-day dermal in human, animal, or just sensitization?

DR. BELSITO: Sensitization, whatever is out there.

DR. BERGFELD: Okay. Anything else?

DR. BELSITO: We just had a question regarding, you know, the insufficiency on the 28-day dermal that we wanted to address with the panel. Do we need it for all of the ingredients, or can we choose a representative ingredient? And we wanted to hear Tom's and Ron's and Lisa's and David's comments on that.

DR. BERGFELD: Ron, you want to start?

DR. SHANK: If the chemists agree, if you have it on the Leaf Extract wouldn't that cover everything else?

DR. BERGFELD: Not the Root.

DR. SHANK: No, not the Root.

DR. PETERSON: I think if we had the composition of what's in the Water, you could read across -- I mean, I don't think you can read across to the Root, but I think if you had some composition information, which we don't have, I think, for the water.

DR. COHEN: Again, are we getting into the same discussion we will have with Tree Tea where there's an aqueous component with its attended set of constituents. And then the hydrophobic component with its constituents. And, perhaps, if we break them out into those two and ask for dermal tox on those two, we might be able to cover all of them.

DR. LIEBLER: My two-cent worth is that if we're going to lean on one thing to test we ought to get something that's (audio distortion), because it's going to have the constituents of concern that applies -- concern for sensitization. For example, the terpenoids which most frequently turn up as causative agents in that.

And, the problem with the waters, it's really hard to tell what it is. The opening description of the water says it an essential oil. So, you know, it's prepared by steam distillation. So if you do a steam distillation and you collect that in a little vial, it usually separates out into an aqueous and organic layer anyway.

So, if we had -- I guess I go back to Ron Shank's suggestion of the Leaf Extract. Because, most of the safe products are a leaf extract. And if it's an extract that captures the greatest percentage of the organics, that would be idea for a lead material for testing.

DR. SLAGA: Honestly, with that Leaf Extract would be the best.

DR. PETERSON: So, I just want to clarify, by Leaf Extract you mean the initial thing before distillation, or are you talking about the oil?

DR. LIEBLER: Oh, it would have to be a product.

DR. PETERSON: Okay.

DR. LIEBLER: Yeah. So, if we're choosing among the products, then, I think, based on the descriptions we had provided, either the Sage Extract or Leaf Extract would be best. And the Leaf Extract, bottom of PDF Page 11, it looks like they're pretty much hydroacoholic extracts, which I think would capture most of what we want. (Audio distorted).

DR. BELSITO: But the extracts, I mean, what's really left is -- is there a pure leaf extract?

DR. LIEBLER: It's one of the ingredients.

DR. SLAGA: Yeah.

DR. BELSITO: Okay.

DR. LIEBLER: Bottom of PDF Page 11, and there are multiple (audio distorted) reported, but they're all hydroacoholic extracts.

DR. BELSITO: Okay, so 28-day dermal on the Leaf Extract would cover all of the other extracts and the waters.

DR. SHANK: Except the Root?

DR. BELSITO: Except the Root.

DR. SLAGA: Except the Root, yeah.

DR. BERGFELD: So that's a consensus agreement? It's a Leaf Extract that we'll ask for the 28-day dermal. And the Root stands alone with all the needs listed.

DR. BELSITO: Right.

DR. COHEN: Yeah, I think it's pretty sensible. It's the highest use and the highest concentration, so it's highly representative.

DR. BERGFELD: I wonder if we could hear from Curt and Ron before we close this discussion. Curt?

DR. KLAASSEN: Yes, I agree with that.

DR. BERGFELD: Ron?

DR. SHANK: Yeah, I agree.

DR. BERGFELD: Okay. Any other discussion before we leave this ingredient? Wilbur are you satisfied with what you have? No, it's Preethi, excuse me.

MS. RAJ: Yes. No worries, no worries. Thank you Dr. Bergfeld. Just to confirm, so, it sounds like the panel would like a 28-day dermal tox on the Leaf Extract ingredient. But you would like method of manufacture, composition, impurities, relevant tox data, gentox and dermal irritation and sensitization data on the Root Extract ingredient.

DR. BERGFELD: That's correct.

DR. COHEN: Yes.

DR. BERGFELD: Everybody endorse that, David. Don?

DR. COHEN: We want composition and impurities on those other items, though, correct? We just narrowed down the dermal tox for the Leaf Extract, but we're not removing the ask for composition and impurities for the other ones as well, correct?

DR. BERGFELD: I don't -- Don? Dan?

DR. LIEBLER: I think we should maintain the request for that at this stage of the report.

DR. SLAGA: Yeah.

DR. BERGFELD: Yeah. Okay.

DR. COHEN: Thank you.

DR. BERGFELD: So, there's an agreement in that. Anything else that we missed in that list, David? Don? Ron? Curt? Lisa? Tom?

DR. SLAGA: No.

DR. BELSITO: No.

DR. BERGFELD: No? Okay, I think we've done it then.

MS. RAJ: Thank you.

DR. BERGFELD: Moving on to the next ingredient in this reports advancing is Levulinic Acid and Sodium Levulinate, Dr. Belsito.

MS. FIUME: First, Dr. Bergfeld, can I go back for a clarification on the safe ingredients?

DR. BERGFELD: Sure.

MS. FIUME: So, and you may have said it and I might've of missed it. So, irritation and sensitization, is that still for all ingredients except the Leaf Oil, or on the Leaf Extract?

DR. BELSITO: Dan, can comment but our feeling was that the Leaf Extract would really be the major ingredient in Flower/Leaf/Stem Extract, so. But, it could be sensitization and irritation, for us at least on the Leaf Extract.

DR. COHEN: We were still asking for it for the Flower/Leaf/Stem, the Water, and the Leaf Water.

DR. BELSITO: Well, we can ask for it and then decide.

DR. COHEN: We can adjudicate it once we have more information to make a better decision.

DR. BELSITO: All right.

DR. BERGFELD: Okay.

MS. FIUME: Thank you.

DR. BERGFELD: Preethi, are you clear on this? Because this has changed a little bit since the beginning of the discussion. Are you clear on what the needs are now?

MS. RAJ: Are you talking to me? Yes.

DR. BERGFELD: Yes.

MS. RAJ: Yes, I think so. So, it sounds like the main ask is for the Leaf Extract the 28-day dermal. It sounds like you also want dermal irritation and sensitization for the Leaf Extract. And you want the whole almost profile of data needs for the Root Extract ingredient.

DR. BERGFELD: Now, I do believe that you added composition and impurities for all the things -- Flower/Leaf/Stem.

DR. COHEN: Yeah, Flower/Leaf/Stem/Water, Water, Leaf Water.

MS. RAJ: Okay, thank you.

DR. BERGFELD: Did we miss anything?

DR. COHEN: I think we got those now.

DR. BERGFELD: Okay. All right. Monice, did we answer the questions?

MS. FIUME: Yes, I believe so. I still think -- I believe the ask for irritation and sensitization data are all ingredients except the Leaf Oil, but then depending on what comes in you'll decide at the next meeting if that's correct -- if you need additional data at least on what was submitted. Is that correct?

DR. BERGFELD: Correct. Well, the needs were as listed but they were very interested in the Leaf Oil getting the 28-day dermal and sensitization and irritation.

DR. BELSITO: Water, not oil.

DR. LIEBLER: Leaf Extract.

DR. BELSITO: Leaf Extract.

DR. COHEN: Actually, thank you for asking again. Just one quick point. Is it possible to get some more information about the eight percent in petrolatum sensitization study and the 25 subjects. Because that one is way over max use and if we had some more data that might (audio distorted) valuable, but --

MS. RAJ: Dr. Cohen, I appreciate you bringing that up. I do think that study was like summary data coming from maybe an even outdated source. So, it might be hard.

DR. COHEN: Okay. Okay, and, yeah, so we can always consider a formulate not to be sensitizing discussion later on.

DR. BERGFELD: Now, I just want to make sure that we know what we've asked for. I need to have you go over it again, Preethi.

MS. RAJ: So, the ask was for a 28-day dermal tox for the Leaf Extract as well as dermal irritation and sensitization for the Leaf Extract. You want composition and impurities for the Flower/Leaf/Stem/Water, and the Leaf Water. Basically all the Flower/Leaf/Stem ingredients, sounds like. And for the Root Extract you kind of want the whole profile because there's nothing.

DR. BERGFELD: Right. I think we got it.

DR. COHEN: We got it.

DR. BERGFELD: Okay. I'm satisfied.

MS. RAJ: Thank you.

DR. BERGFELD: Thank you, very much.

Safety Assessment of *Salvia officinalis* (Sage)-Derived Ingredients as Used in Cosmetics

Status: Draft Tentative Report for Panel Review
Release Date: November 10, 2021
Panel Meeting Date: December 6 -7, 2021

The Expert Panel for Cosmetic Ingredient Safety members are: Chair, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; David E. Cohen, M.D.; Curtis D. Klaassen, Ph.D.; Daniel C. Liebler, Ph.D.; Lisa A. Peterson, Ph.D.; Ronald C. Shank, Ph.D.; Thomas J. Slaga, Ph.D.; and Paul W. Snyder, D.V.M., Ph.D. The Cosmetic Ingredient Review (CIR) Executive Director is Bart Heldreth, Ph.D. This safety assessment was prepared by Preethi S. Raj, M.Sc., Senior Scientific Analyst/ Writer, CIR.

1620 L Street, NW, Suite 1200 ♢ Washington, DC 20036-4702 ♢ ph 202.331.0651 ♢ fax 202.331.0088 ♢
cirinfo@cir-safety.org

ABSTRACT

The Expert Panel for Cosmetic Ingredient Safety (Panel) assessed the safety of *Salvia officinalis*-derived ingredients as used in cosmetic formulations. These ingredients are reported to function mostly as skin conditioning agents and fragrance ingredients. Because final product formulations may contain multiple botanicals, each containing the same constituents of concern, formulators are advised to be aware of these constituents and to avoid reaching levels that may be hazardous to consumers. Industry should use current good manufacturing practices to minimize impurities that could be present in botanical ingredients. The Panel reviewed data relevant to the safety of these ingredients in cosmetic formulations, and concluded….[TBD].

INTRODUCTION

This assessment reviews the safety of 12 *Salvia officinalis*-derived ingredients as used in cosmetic formulations:

Salvia Officinalis (Sage) Extract
Salvia Officinalis (Sage) Flower/Leaf/Stem Extract
Salvia Officinalis (Sage) Flower/Leaf/Stem Juice
Salvia Officinalis (Sage) Flower/Leaf/Stem Water
Salvia Officinalis (Sage) Leaf
Salvia Officinalis (Sage) Leaf Extract
Salvia Officinalis (Sage) Leaf Oil
Salvia Officinalis (Sage) Leaf Powder
Salvia Officinalis (Sage) Leaf Water
Salvia Officinalis (Sage) Oil
Salvia Officinalis (Sage) Root Extract
Salvia Officinalis (Sage) Water

According to the web-based *International Cosmetic Ingredient Dictionary and Handbook* (wINCI; *Dictionary*), various functions are reported for these ingredients, with skin-conditioning agent and fragrance ingredient being the most common; other reported functions include as an antioxidant, oral care agent, a flavoring agent, and an exfoliant (Table 1).[1] No cosmetic function is reported for Salvia Officinalis (Sage) Leaf.

The Panel does not typically review ingredients that function only as fragrance ingredients, because, as fragrances, the evaluation of the safety of these ingredients is the purview of the Research Institute for Fragrance Materials (RIFM). Salvia Officinalis (Sage) Flower/Leaf/Stem Water and Salvia Officinalis (Sage) Water are reported to function only as fragrance ingredients in cosmetics, according to the wINCI Dictionary (see Table 1). The RIFM review status of these ingredients is uncertain.

These ingredients are derived from the same species, and have therefore been grouped together in this assessment. *Salvia officinalis* may contain hundreds of constituents, some of which have the potential to cause toxic effects. For example, thujone is a known neurotoxicant and terpenes have the potential to cause dermal sensitization.[2,3] In this assessment, the Panel is reviewing the potential toxicity of each of *Salvia officinalis*-derived ingredients as a whole, complex substance; toxicity from single components may not predict the potential toxicity of botanical ingredients.

Some of the ingredients reviewed in this safety assessment may be consumed as food, and daily exposure from food would result in much larger systemic exposures than those from use in cosmetic products. Although oral studies are included herein, the primary focus of this safety assessment is on the potential for effects from topical exposure to these ingredients as used in cosmetics

This safety assessment includes relevant published and unpublished data that are available for each endpoint that is evaluated. Published data are identified by conducting an exhaustive search of the world's literature. A listing of the search engines and websites that are used and the sources that are typically explored, as well as the endpoints that the Expert Panel for Cosmetic Ingredient Safety (Panel) typically evaluates, is provided on the Cosmetic Ingredient Review (CIR) website (https://www.cir-safety.org/supplementaldoc/preliminary-search-engines-and-websites; https://www.cir-safety.org/supplementaldoc/cir-report-format-outline). Unpublished data are provided by the cosmetics industry, as well as by other interested parties.

Much of the data included in this safety assessment is described on the European Chemicals Agency (ECHA) website and in the 2016 European Medicines Agency (EMA) monographs on *Salvia officinalis*.[4-6] Please note that the ECHA website and EMA monographs provide summaries of information from the industry and toxicological studies, and it is those summary data that are reported in this safety assessment when ECHA and EMA are cited. The CAS No. 84082-79-1 referenced in the ECHA dossier is generic, and corresponds to several of the ingredients in this report. However, based on the International Union of Pure and Applied Chemistry (IUPAC) definition for this substance in ECHA, these data were deemed to refer to the Salvia Officinalis (Sage) Flower/Leaf/Stem Water ingredient, and have been described as such, when cited in this report.

The cosmetic ingredient names, according to the *Dictionary*, are written as listed above, without italics. In many of the published studies, it is not known how the substance being tested compares to the cosmetic ingredient. Therefore, if it is not known whether the chemicals being discussed are cosmetic ingredients, the test substances will be identified by the standard taxonomic practice of using italics to identify genus and species (i.e., *Salvia officinalis* extract). However, if it is known that the substance is a cosmetic ingredient, the International Nomenclature Committee (INC) terminology (i.e., title case and no

italics) "Salvia Officinalis…" (e.g., Salvia Officinalis (Sage) Extract) will be used. When referring to the plant from which these ingredients are derived, the standard scientific practice of using italics will be followed (i.e., *Salvia officinalis*).

CHEMISTRY

Definition and Plant Identification

The definitions of the 12 *Salvia officinalis* (sage)-derived ingredients reviewed in this assessment are presented in Table 1.[1] Most of the ingredients included in this assessment have the generic CAS No. 84082-79-1; however, both Salvia Officinalis (Sage) Leaf Oil and Salvia Officinalis (Sage) Oil also have the CAS No. 8022-56-8 (generic).

Generically, the root is defined as a plant organ that lacks leaves and nodes, is usually underground, and absorbs and transports water and nutrients.[1] The flower is defined as the reproductive shoot in flowering plants, and is usually composed of sepals, petals, stamens, and pistil(s). The stem is defined as a slender or elongated structure, which supports a plant, fungus, or plant organ. The leaves are defined as the flattened photosynthetic organs of a plant, which are attached to the plant stems.

Salvia officinalis is a plant in the Lamiaceae (i.e., mint) family and Nepotoideae subfamily.[7] Commonly referred to as sage, or Dalmatian sage, *Salvia officinalis* is native to the Mediterranean and Middle Eastern regions, and is cultivated throughout the Americas and Europe, including, Spain, Italy, Yugoslavia, Greece, Albania, Argentina, Germany, France, Malta, Turkey, England, and Canada.[8,9] It is a medium-size perennial evergreen herb, which grows as a bush, having a quadrangular base, with many branches.[9] The plant can grow up to 60 - 70 cm in height. The leaves are arranged in an opposite and whorled pattern, and are oblong, 2.5 - 6.0 cm long, wrinkled, and light green to silver gray in color. *Salvia officinalis* blooms in early summer, and has blue, white, or purple flowers that have two lips, are up to 3 cm long, and are attached in whorls on short, upright flower spikes.

Chemical Properties

A summary of chemical properties described for *Salvia officinalis* (sage)-derived ingredients are provided in Table 2.

Salvia Officinalis (Sage) Leaf Extract

A supplier described a trade mixture containing Salvia Officinalis (Sage) Leaf Extract (dry extract between 1.8 – 3%), propylene glycol, and water as a brown to brown-orange translucent liquid, with slight precipitate.[10] The mixture was further described to be miscible in water and 50% v/v alcohol, non-miscible in mineral and vegetal oils, have a pH of 4 – 5, a refractive index of 1.410 – 1.420, and, at 20 °C, have a density of 1.045 – 1.058 g/cm^3.

Method of Manufacture

Some of the methods below are general to the processing of *Salvia officinalis* (sage), and it is unknown if they apply to cosmetic ingredient manufacturing.

Salvia Officinalis (Sage) Extract

An aqueous infusion was prepared by adding 150 ml of boiling water to an herbal sachet containing only 1.5 g of whole *Salvia officinalis* leaves (not crushed).[11] The infusion was allowed to steep for 15 min and shaken every 5 min, and, filtered with a disposable polyester filter, with 0.20 µm pore size.

Salvia Officinalis (Sage) Flower/Leaf/Stem Extract

In a preparation of *Salvia officinalis* flower extract, fresh flowers were harvested at the height of bloom, cut, and extracted with 80% methanol/water (v/v).[12] The hot extraction occurred in a 3-stage procedure (90 °C in water bath), under reflux for 10 min, to obtain a yield of 100 mg/ml extract; each extract was filtered using a 0.45 µm nylon membrane filter.

In the preparation of an aqueous *Salvia officinalis* leaf extract, 1 g of dried aerial *Salvia officinalis* was added to 200 ml of boiling water, and the solution was left to stand at room temperature for 5 min, filtered under reduced pressure, frozen, and lyophilized.[13] In the same study, a preparation of a methanolic *Salvia officinalis* extract was obtained by stirring a 1 g sample of dried aerial *Salvia officinalis* with 30 ml of a methanol/water (80:20 v/v) solvent at 25 °C and 150 rpm for 1 h, and then filtering the extract. A second step extraction was obtained with an additional 30 ml of the solvent; extracts from both steps were combined, evaporated at 35 °C under reduced pressure, and further lyophilized. The lyophilized methanolic *Salvia officinalis* extracts were re-dissolved in methanol/water (80:20, v/v); the aqueous *Saliva officinalis* extracts were re-dissolved in water. The resulting stock solutions contained a 20 mg/ml concentration of *Salvia officinalis* extract.

Salvia Officinalis (Sage) Flower/Leaf/Stem Juice

Salvia Officinalis (Sage) Flower/Leaf/Stem Juice is the juice expressed from the flowers, leaves, and stems of *Salvia officinalis*.[1]

Salvia Officinalis (Sage) Flower/Leaf/Stem Water

Salvia Officinalis (Sage) Leaf Water was described by a supplier as an aqueous extract obtained by steam distillation of the *Salvia officinalis* leaves.[14] Salvia Officinalis (Sage) Flower/Leaf/Stem Water is the aqueous solution of the steam distillate obtained from the flowers, leaves, and stems of *Salvia officinalis*.[1]

Salvia Officinalis (Sage) Leaf

Salvia Officinalis (Sage) Leaf is the leaves of *Salvia officinalis*.[1]

Salvia Officinalis (Sage) Leaf Extract

One supplier described a trade mixture containing Salvia Officinalis (Sage) Leaf Extract (dry extract between 1.8 – 3%), propylene glycol, and water as a hydroglycolic extract obtained from *Salvia officinalis* leaves, via controlled extraction using propylene glycol and water.[10] In another method of manufacture for Salvia Officinalis (Sage) Leaf Extract, described by a supplier, dried leaves are extracted with eluent(s), such as water, butylene glycol, glycerin, propylene glycol, or carthamus tinctorius (safflower) seed oil, under appropriate temperature conditions, to yield a concentrate.[15] This concentrate is then blended with the desired diluent(s) and is preserved to yield the final ingredient. Both the intermediate concentrate and the final ingredient are evaluated for physiochemical properties, contaminants, and specification requirements.

A supplier provided 5 methods of manufacture for 5 separate Salvia Officinalis (Sage) Leaf Extracts.[16] In general, dried *Salvia officinalis* leaves were extracted with either a 30% or 90 vol% ethanolic solution or with a 50 vol% 1,3-butylene glycolic solution, and filtered to produce a filtrate. The resulting filtrate (sometimes called a concentrate) went through a sedimentation process, and was filtered and adjusted as needed, prior to packaging. In one of the described methods, the extract concentrate was dissolved in squalane prior to sedimentation.

Salvia Officinalis (Sage) Leaf Oil

Salvia Officinalis (Sage) Leaf Oil is the volatile oil obtained from the leaves of *Salvia officinalis*.[1]

Salvia Officinalis (Sage) Oil

A *Salvia officinalis* oil sample was prepared by first drying and grinding the aerial parts of *Salvia officinalis* to yield 250 g of powder.[17] The powder was subject to hydrodistillation for 3 h using a Clevenger apparatus; the eluted oil was dried over anhydrous sodium sulfate and preserved in a sealed vial at 4 °C.

Salvia Officinalis (Sage) Leaf Powder

Salvia Officinalis (Sage) Leaf Powder is the powder obtained from the dried ground leaves of *Salvia officinalis*.[1]

Salvia Officinalis (Sage) Leaf Water; Salvia Officinalis (Sage) Water

Salvia Officinalis (Sage) Leaf Water and Salvia Officinalis (Sage) Water are both defined as aqueous solutions of the steam distillate obtained from *Salvia officinalis*.[1]

Salvia Officinalis (Sage) Root Extract

Salvia Officinalis (Sage) Root Extract is the extract of the roots of *Salvia officinalis*.[1]

Composition and Impurities

The determination of individual constituents and natural content in *Salvia officinalis*-derived ingredients varies considerably depending on the extraction solvent and method, part of the plant, growth stage, and time of harvest.[11,18-21]

The European Food Safety Authority issued a recommended maximum residue level of 20 mg/kg ametoctradin, a fungicide, in *Salvia officinalis*.[22,23] In an analysis of pesticide residues, commercial samples of *Salvia officinalis* in Poland were found to have boscalid, chlorpyrifos, 1,1,1-tricloro-2,2-*bis*(4-chlorophenyl)ethane, dimethoate, and indoxacarb in negligible amounts (0.02 - 0.05 mg/kg).[24] The researchers concluded that the presence of these contaminants in herbal infusions would be minimal.

Salvia Officinalis (Sage) Extract

An aqueous extract of *Salvia officinalis* was reported to have a total phenolic compound content of 158.9 ± 38.0 µg gallic acid equivalents.[25]

Salvia Officinalis (Sage) Leaf Extract

Theoretical calculations made by a supplier indicate that a trade mixture of propylene glycol, water, and Salvia Officinalis (Sage) Leaf Extract contains less than 10 ppm geraniol, less than 125 ppm limonene, and less than 225 ppm linalool.[10] Borneol, cineol, luteolin, apigenin, caffeic acid, and rosmarinic acid were identified as being present in this extract.

In an industry assessment conducted on the concentrate in an alcohol base, no heavy metals or pesticide residues were detected in Salvia Officinalis (Sage) Leaf Extract.[15] Similarly, testing the concentrate of Salvia Officinalis (Sage) Leaf Extract, in an alcohol base, for the 26 allergens identified by the European Union yielded a universal threshold of < 10 ppm – 0.001%.[15]

Flavonoids and tannins were the primary components identified in 4 Salvia Officinalis (Sage) Leaf Extracts, prepared using 30% or 90% ethanol, or 50% 1,3-butylene glycolic solution.[16] The levels of heavy metals and arsenic found in 4 of these Salvia Officinalis (Sage) Leaf Extract samples were not more than 20 ppm and 2 ppm, respectively. In a fifth sample of Salvia Officinalis (Sage) Leaf Extract, in which the intermediate concentrate was dissolved in squalane, the primary

components were also flavonoids and tannins, and detected heavy metal and arsenic levels were no more than 10 ppm and 2 ppm, respectively.

Salvia Officinalis (Sage) Leaf Water

Theoretical calculations made by a supplier, indicate that a Salvia Officinalis (Sage) Leaf Water contains less than 10 ppm geraniol, less than 125 ppm limonene and less than 225 ppm linalool.[14] The presence of borneol was also identified in this ingredient.

Salvia Officinalis (Sage) Leaf Oil

The main classes of constituents identified in an Albanian sample of *Salvia officinalis* leaf oil were monoterpene hydrocarbons (21.5%), oxygenated monoterpenoids (66.5%), sesquiterpene hydrocarbons (9.4%), and oxygenated sesquiterpenoids (2.4%).[26] The major components in this *Salvia officinalis* leaf oil sample were α- and β-thujone, of which α-thujone was proportionally higher.

Salvia Officinalis (Sage) Oil

According to the EMA monograph, the principal components of *Salvia officinalis* oil are thujone, 1,8-cineole, and camphor; in 25 different commercial sources of sage leaves, camphor levels varied from 7 - 50% .[5] The main classes of constituents in *Salvia officinalis* oil are identified as terpenoids, hydroxycinnamic acid derivatives, flavonoids, phenolic glycosides, and polysaccharides.

The major components of a *Salvia officinalis* oil from Iran were identified as α-thujene (13.96%), α-pinene (12.91%), and 1,8-cineole (22.91%).[17] Percent composition of both *Salvia officinalis* leaf oil and *Salvia officinalis* oil samples is provided in Table 3.

USE

Cosmetic

The safety of the cosmetic ingredients addressed in this assessment are evaluated based on data received from the US Food and Drug Administration (FDA) and the cosmetics industry on the expected use of these ingredients in cosmetics. Use frequencies of individual ingredients in cosmetics are collected from manufacturers and reported by cosmetic product category in the FDA Voluntary Cosmetic Registration Program (VCRP) database. Use concentration data are submitted by the cosmetic industry in response to a survey, conducted by the Personal Care Products Council (Council), of maximum reported use concentrations by product category.

According to 2021 VCRP survey data, Salvia Officinalis (Sage) Leaf Extract is reported to have the greatest frequency of use; it is reported to be used in 213 formulations, 116 of which are rinse-off formulations[27] (Table 3). The other ingredients have 87 or fewer reported uses. The results of the concentration of use survey conducted by the Council in 2020 indicate Salvia Officinalis (Sage) Leaf Extract also has the highest reported concentration of use; it is used at up to 0.38% in other skin care preparations.[28,29] Five *Salvia officinalis* (sage)–derived ingredients which are not reported to be in use are listed in Table 4.

A few of the *Salvia officinalis* (sage)-derived ingredients are reported to be used in products applied near the eye, such as Salvia Officinalis (Sage) Leaf at up to 0.0001% in eye lotions, and in products that can result in incidental ingestion (e.g., Salvia Officinalis (Sage) Oil at up to at 0.011% in dentifrices). Additionally, some of the ingredients are used in formulations that could come in contact with mucous membranes, such as Salvia Officinalis (Sage) Oil at up to 0.02% in bath soaps and detergent.

Furthermore, some of the *Salvia officinalis* (sage)-derived ingredients are used in cosmetic spray formulations, and could possibly be inhaled. For example, Salvia Officinalis (Sage) Leaf Extract is reported to be used in pump and aerosol hair sprays at up to 0.0001% and 0.002%, respectively, Salvia Officinalis (Sage) Extract is reported to be used in underarm deodorant spray at up to 0.0011%, and Salvia Officinalis (Sage) Leaf Oil is reported to be used in pump spray suntan formulations at up to 0.012%. In practice, 95% to 99% of the droplets/particles released from cosmetic sprays have aerodynamic equivalent diameters > 10 µm, with propellant sprays yielding a greater fraction of droplets/particles < 10 µm compared with pump sprays.[30,31] Therefore, most droplets/particles incidentally inhaled from cosmetic sprays would be deposited in the nasopharyngeal and thoracic regions of the respiratory tract and would not be respirable (i.e., they would not enter the lungs) to any appreciable amount.[32 33] There is some evidence indicating that deodorant spray products can release substantially larger fractions of particulates having aerodynamic equivalent diameters in the range considered to be respirable.[32] However, the information is not sufficient to determine whether significantly greater lung exposures result from the use of deodorant sprays, compared to other cosmetic sprays.

All of the ingredients named in the report are not restricted from use in any way under the rules governing cosmetic products in the European Union.[34] However, the 49th Amendment of the International Fragrance Association (IFRA) standard states that thujone is expected to occur naturally at 8 - 33% in *Salvia officinalis* oil and 2.5 - 10% in *Salvia officinalis* oleoresin, and can therefore be restricted if found at higher levels in these ingredients.[35] Furthermore, IFRA limits

the levels of thujone in finished products, depending on the product category, ranging from 0.0053% in several skin contact products to 9.5% in products not intended for direct skin contact.

Non-Cosmetic

Salvia officinalis oil and *Salvia officinalis* leaf have generally recognized as safe (GRAS) status as natural seasonings, according to the US FDA[21CFR § 182.20; 21CFR § 582.10]. Additionally, *Salvia officinalis* oil is listed as a GRAS flavoring substance by the Flavor Extract Manufacturers Association.[36] Also, sage oil may have previously been used as an active ingredient in over-the-counter, astringent drug products; however, the FDA citation states that there are inadequate data to establish general recognition of the safety and effectiveness of the ingredient for this specified use [21CFR § 310.545]. The *Salvia officinalis* plant is a common potherb; *Salvia officinalis* leaves are typically used for flavoring meat, fish, and poultry dishes.[37]

According to a 2016 EMA herbal monograph of *Salvia officinalis* L., folium, an aqueous infusion of *Salvia officinalis* is applied to the skin in traditional medicine for the relief of minor inflammation.[6] The monograph also describes *Salvia officinalis* being consumed orally as a dry/liquid extract or tincture, for the treatment of heartburn, bloating, excessive sweating, and relief of inflammation of the mouth or throat. Most medicinal uses of *Salvia officinalis* products in Europe are marketed in varied forms, at a daily dose of 1.5 - 2.5 g/d.[5] In Spain, a dry extract of *Salvia officinalis* is marketed for the treatment of excessing sweating at a dose of 360 mg/d (equivalent to 500 - 800 mg of dried *Salvia officinalis* leaves). Pure *Salvia officinalis* oil and extract consumption is contraindicated during pregnancy, due to its abortifacient and emmenagogic properties.[5]

TOXICOKINETIC STUDIES

No relevant toxicokinetic studies on *Salvia officinalis*-derived ingredients were found in the published literature, and unpublished data were not submitted. In general, toxicokinetic data are not expected to be found on botanical ingredients because each botanical ingredient is a complex mixture of constituents.

TOXICOLOGICAL STUDIES

Acute Toxicity Studies

Dermal

Salvia Officinalis (Sage) Leaf Extract

The acute dermal LD_{50} of Salvia Officinalis (Sage) Leaf Extract, eluted in 50% 1,3-butylene glycolic solution, was determined to be > 2000 mg/kg in 5 mice.[16] No further details were provided.

Salvia Officinalis (Sage) Oil or Salvia Officinalis (Sage) Leaf Oil

The acute dermal LD_{50} of *Salvia officinalis* oil or *Salvia officinalis* leaf oil (unclear from source) was determined to be > 5000 mg/kg, in rabbits.[36] No further details were provided.

Oral

Salvia Officinalis (Sage) Extract

A single oral dose of an hydroalcoholic extract of *Salvia officinalis* was administered to groups of 6 female Swiss mice, at doses of 5, 50, 500, or 5000 mg/kg.[38] No visible signs of toxicity were observed. All animals in the 5000 mg/kg group showed piloerection and diarrhea lasting up to 3 h after treatment. One animal from the 5000 mg/kg group died before 48 h. The acute oral LD_{50} in female Swiss mice was determined to be 44,760 mg/kg.

Salvia Officinalis (Sage) Flower/Leaf/Stem Extract

Six albino female rats were administered a one-time dose of 1% v/v Tween 80 in distilled water (control), or 500-2000 mg/kg bw of an ethanolic *Salvia officinalis* leaf and stem extract.[39] Animals were observed for symptoms of toxicity or mortality for 14 d; the extract was considered not toxic at the maximum dose of 2000 mg/kg bw. No further details were provided.

In an acute oral toxicity study, 4 groups of 10 male Wistar rats were administered an oral, undiluted, dose of *Salvia officinalis* flower/leaf/stem water at 1290, 2020, 3200, or 5000 mg/kg bw.[4] Mortality was observed for up to 14 d after treatment, after which all surviving animals were killed. One animal died from the 1290 mg/kg group, 4 died from the 2020 mg/kg group, 7 died from the 3200 mg/kg group, and 9 animals died from the 5000 mg/kg group. Lethargy was observed in all rats.

Salvia Officinalis (Sage) Oil or Salvia Officinalis (Sage) Leaf Oil

The acute oral LD_{50} of *Salvia officinalis* oil or *Salvia officinalis* leaf oil (unclear from source) was determined to be 2600 mg/kg bw, in rats.[36] No further details were provided.

Short-Term Toxicity Studies

Oral

Salvia Officinalis (Sage) Oil or Salvia Officinalis (Sage) Leaf Oil

In an 8-wk study using groups of 5 white rats (sex and strain not specified), a daily dose of 250 mg/kg bw *Salvia officinalis* oil was well tolerated when given by oral administration.[5] Upon increase of the daily dose to 500 mg/kg bw/d, convulsions occurred in some animals. Upon increase to 1000 mg/kg bw/d, most animals died, and all animals died when the dose was increased to 1250 mg/kg bw/d (timing and duration of all 3 dose increases not provided). The no-observed-adverse-effect-level (NOAEL) of *Salvia officinalis* oil was determined to be 250 mg/kg bw/d, under the conditions of this study.

DEVELOPMENTAL AND REPRODUCTIVE TOXICITY STUDIES

Oral

Salvia Officinalis (Sage) Extract

Distilled water or 30 mg/kg bw/d hydroalcoholic extract (70% ethanol) of *Salvia officinalis* was administered orally, via gavage, to groups of 7 female Wistar rats for 30 d.[40] Estrous cycle changes were monitored with daily vaginal smears. At the end of the observation period, animals in the estrus phase of the estrous cycle were dissected under deep anesthesia. Blood samples were taken to be analyzed in a hormonal assay. Right and left mammary glands from the pelvic region were excised, from which whole mount and formalin-fixed slides were prepared, respectively. No significant differences in blood estradiol or progesterone were observed, and a decrease in the duration of estrous cycles in *Salvia officinalis* extract-treated rats was not statistically significant. An increased number of alveolar buds and lobules in the whole mount slides, as well as an increase in the number and diameter of ducts in the histological sections of rats treated with *Salvia officinalis* extract, were statistically significant.

Sage Officinalis (Sage) Flower/Leaf/Stem Extract

The possible estrogenic effects of an ethanolic *Salvia officinalis* leaf and stem extract were examined in groups of 6 immature ovariectomized female rats for 7 d.[39] One control group was not ovariectomized, while a second control group served as ovariectomized controls; both control groups were administered 1% v/v Tween 80 in distilled water, while treatment animals were dosed with 50, 100, or 200 mg/kg bw *Salvia officinalis* leaf and stem extract, via gavage. An additional group was administered an i.p. dose of 1 µg/d of estradiol, as standard drug treatment. On day 8, vaginal smears were collected from all animals for evaluation of estrus cycle phase and blood samples were drawn to assess serum levels of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Then, after the animals were killed, the uteri underwent immunohistochemical staining for estrogen receptors, dissection to examine uterine histology, and were weighed to calculate relative uterus weights. Vaginal smears from rats treated with the *Salvia officinalis* leaf and stem extract exhibited varying estrus cycle phases, compared to ovariectomized controls. Serum levels of LSH and FSH were also significantly reduced in the 200 mg/kg bw group (41.7% and 49.1%, respectively). While a decreased percentage of cells stained positively for estrogen receptors in the 50 mg/kg group (compared to the non-ovariectomized controls), significant increases in the percentage of positively stained cells were seen in the uterine tissue of rats treated with 100 and 200 mg/kg bw leaf and stem extract. Increased endometrial thickness, associated with stromal inflammation, was seen in both rats treated with estradiol and the *Salvia officinalis* leaf and stem extract, and dose-dependent increases in endometrial thickness, were seen in the latter group of treated rats, suggesting uterotrophic effects. Similarly, treatment with the *Salvia officinalis* leaf extract exhibited a significant dose-dependent increase in uterine weights.

Salvia Officinalis (Sage) Oil

Twenty-four female ICR mice received a daily dose of 0.25% *Salvia officinalis* oil (equivalent to 375 mg/kg/d), in rodent feed, for 14 d.[41] After this initial 2-wk period, 3 females were housed with 1 male for 8 d, to induce fertilization. Unfertilized dams were excluded. Post-mating, 13 fertilized females pretreated with *Salvia officinalis* oil were fed, *ad libitum,* a diet containing *Salvia officinalis* oil, while 13 control females were fed a diet with 1% edible soya oil (vehicle), till day 4 of gestation. Dams were killed on day 4 of gestation, and the embryos were recovered at the blastocyst stage of development and prepared for morphological analyses. The number and distribution of pre-implantation embryo nuclei, and the percentage of normal and dead cells, were measured as markers of growth and development. A significant decrease in embryo cell distribution, according to nucleus number, was observed in dams which consumed *Salvia officinalis* oil. Dam weights and the proportion of dead cells in embryos were not affected.

GENOTOXICITY STUDIES

Details of the in vitro genotoxicity studies summarized below are described in Table 5.

Salvia officinalis flower/leaf/stem water was not found genotoxic when tested at doses up to 5000 µg/plate, in two bacterial reverse mutation assays.[4,42] Salvia Officinalis (Sage) Leaf Extract, eluted in 50% 1,3-butylene glycolic solution, was not genotoxic in a reverse mutation test using *Salmonella typhimurium* strains TA98, TA100, TA1535, TA1537, or *Escherichia coli* WP2 uvrA at up to 5000 µg/0.1 ml/plate.[16] *Salvia officinalis* oil was not found genotoxic in a chromosome

aberration test at doses up to 0.15 mg/ml.[43] In one Ames test, *Salvia officinalis* oil, in doses of 91, 183, or 457 µg, was shown to significantly inhibit bacterial growth, however, was not considered genotoxic.[44]

ANTI-MUTAGENICITY STUDIES

In Vitro

Salvia Officinalis (Sage) Extract

The anti-mutagenic potential of *Salvia officinalis* extract was tested in 3 groups of 5 male C3H mice.[45] Animals were first intraperitoneally dosed with 1 mg/kg of a positive mutagen, mitomycin C (MMC), and then with 25, 50, or 100 µl/kg *Salvia officinalis* extract. Bone marrow was extracted 24 h after treatment and tested for aberrations. Treatment with 25 and 50 µl/kg *Salvia officinalis* extract immediately after MMC exposure significantly decreased the frequency of cells in metaphase with chromosome aberrations, relative to cells only treated with MMC. However, the 100 µl/kg dose of *Salvia officinalis* extract was shown to be cytotoxic by itself, and when administered after MMC (confirmed in a preliminary test).

CARCINOGENICITY STUDIES

No relevant carcinogenicity studies on *Salvia officinalis*-derived ingredients were found in the published literature, and unpublished data were not submitted.

ANTI-CARCINOGENICITY STUDIES

Animal

Salvia Officinalis (Sage) Leaf Extract

In a tumorigenesis study, 20 female Wistar rats, which were previously induced with dimethyl-benzanthracene to develop breast cancer, were orally dosed with a hydroalcoholic *Salvia officinalis* leaf extract (concentration not provided) for 6 mo.[46] The control group consisted of 8 rats which received 3 ml of sunflower oil, every 2 d, for 3 consecutive wk. Cancer stage and progression was analyzed throughout the course of the study. Cancerous lobule counts were significantly lower in the *Salvia officinalis* leaf extract treated group, compared to controls in the fourth and sixth mo of treatment.

OTHER RELEVANT STUDIES

Cytoxicity

Salvia Officinalis (Sage) Leaf Oil

The cytotoxic activity of *Salvia officinalis* leaf oil in various cancer cell lines was determined using half maximal inhibitory concentration (IC_{50}) values.[47] The IC_{50} values of *Salvia officinalis* leaf oil were 554.5 ± 1.5 µg/ml against the MCF-7 breast cancer cell line, 394.6 ± 1.4 µg/ml, against the HCT-116 colon cancer cell linE, and 207.5 ± 0.8 µg/ml against the RAW264.7 murine macrophage cell line.

Salvia Officinalis (Sage) Oil

Salvia officinalis oil was determined to have an IC_{50} value of 367.43 µg/ml ± 1.5 µg/ml against a C32 human melanoma cell line, and an IC_{50} of 108.70 ± 1.2 against an ACHN renal carcinoma cell line.[48]

DERMAL IRRITATION AND SENSITIZATION STUDIES

Irritation

In Vitro

Salvia Officinalis (Sage) Flower/Leaf/Stem Water

The in vitro skin corrosion reconstructed human epidermis (Rhe) test was performed, in accordance with Organisation for Economic Cooperation and Development (OECD) test guideline (TG) 431, using 2 separate, 0.60 cm^2, reconstituted human epidermis tissue surfaces (epiCS®).[4] Tissues were exposed to 50 µl of undiluted *Salvia officinalis* flower/leaf/stem water for 3 min and 1 h, and were rinsed with 20 ml of Dulbecco's phosphate-buffered saline (DPBS) after each exposure. Cell viability was measured via a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) colorimetric assay. Mean percent cell viability, of both test tissue replicates, were 100% and 39.83%, compared to 20.26% and 0% in positive control replicates exposed to 8 N potassium hydroxide. Based on these results, the test substance was not considered corrosive to skin.

Another in vitro skin irritation Rhe test was performed, in accordance with OECD TG 439, using 3 separate, 0.50 cm^2, reconstituted human epidermis tissue surfaces (EpiSkin SA, RHE/S/17).[4] Tissues were exposed to 16 µl of undiluted *Salvia officinalis* flower/leaf/stem water for 42 min, rinsed with 25 ml of DPBS, and incubated for 42 h in fresh medium. Cell viability was measured in a MTT colorimetric assay. The mean percent viability of treated tissues was 2.1%, compared to 2.9% in the positive control replicates exposed to 5% sodium dodecyl sulfate. Under these test conditions, the test substance was classified as "irritating to the skin" or "corrosive to the skin".

Animal

Salvia Officinalis (Sage) Leaf Extract

Undiluted and 10% Salvia Officinalis (Sage) Leaf Extract, eluted in 50% 1,3-butylene glycolic solution, was non-irritating to the skin of 3 rabbits.[16] No further details provided.

Salvia Officinalis (Sage) Oil or Salvia Officinalis (Sage) Leaf Oil

Undiluted *Salvia officinalis* oil, or *Salvia officinalis* leaf oil (unclear from source), was moderately irritating when applied to intact, or abraded, rabbit skin, under occlusion for 24 h.[36] No further details provided.

Human

Salvia Officinalis (Sage) Oil or Salvia Officinalis (Sage) Leaf Oil

One irritation reaction occurred in a 24-h patch test of undiluted *Salvia officinalis* oil, or *Salvia officinalis* leaf oil (unclear from source), using 20 subjects.[36,49] No further details provided. In another study, *Salvia officinalis* oil, or *Salvia officinalis* leaf oil, tested at 8% in petrolatum, did not produce irritation in a 48-h occlusive patch test of human subjects.[36] No further details were provided.

Sensitization

Human

Salvia Officinalis (Sage) Leaf Extract

The skin sensitization potential of a product containing 0.005% Salvia Officinalis (Sage) Leaf Extract was evaluated in an occlusive human repeated insult patch test (HRIPT) completed in 53 subjects, 25% of whom were reported to have self-perceived sensitive skin; the test article was applied at a 1% dilution in distilled water.[50] Nine, 24-h applications of the test article (0.2. ml; 0.05 ml/cm^3) were made to the back over a 3-wk induction period. After a 2-wk non-treatment period, a 24-h challenge application was made to a previously untreated site in the same manner as the induction applications, and reactions were scored at 24 and 72 h after application. Neither irritation nor sensitization occurred during the course of the study. The test material was considered a non-irritant and non-sensitizer.

Salvia Officinalis (Sage) Oil

In a similar manner, an occlusive HRIPT of a body lotion containing 0.03% Salvia Officinalis (Sage) Oil was completed in 53 subjects.[51] Nine, undiluted induction applications of 0.1 – 0.15 g of the test article were made (each for 24 h) over 3-wk. After a 2-wk non-treatment period, a challenge application was made to a previously untreated site and reactions were scored 24 and 72 h after application. No signs of skin reactivity were observed during the induction or challenge phase. The test article was deemed non-irritating and non-sensitizing.

Salvia Officinalis (Sage) Oil or Salvia Officinalis (Sage) Leaf Oil

A maximization test was carried out on 25 subjects.[36] *Salvia officinalis* oil, or *Salvia officinalis* leaf oil, tested at a concentration of 8% in petrolatum did not cause sensitization. No further details provided.

OCULAR IRRITATION STUDIES

In Vitro

Salvia Officinalis (Sage) Flower/Leaf/Stem Water

The potential of *Salvia officinalis* flower/leaf/stem water to cause eye irritation was evaluated in a reconstructed human cornea-like epithelium test.[4] The test was performed in accordance with OECD TG 492, using an EpiOcular™ three-dimensional human cornea model. Fifty µl of the undiluted test article was applied to 2 living tissue models (duplicate runs), pretreated with DPBS, for 30 min. The treated tissue was then washed out with DPBS and post-incubated under normal medium and culture conditions for 2 h. Cell viability was measured via an MTT assay; positive controls were treated with methyl acetate. In the first test, viability was 60.34%, compared to 24.44% in positive controls. In the second test, viability was 80.96% compared to 18.36% in the positive controls. The test substance was not considered an ocular irritant.

CLINICAL STUDIES

Case Reports

Salvia Officinalis (Sage) Extract

An 83-yr old woman presented with swelling and redness of the lips and the surrounding area, followed by tightness and a burning sensation, which persisted for 3 mo.[52] The allergic reaction was attributed to a lip balm she had previously used. The subject was patch tested with the European baseline, cosmetic and bakery series, and with the suspected lip balm. On day 2 and 4, positive reaction readings were noted only for the lip balm. The subject was then patch tested with manufacturer-supplied *Salvia officinalis* extract and polygonum, each separately in water and in petrolatum. Positive reactions only occurred to *Salvia officinalis* extract; further patch tests of the lip balm, *Salvia officinalis* extract, and polygonum were negative in 20 other subjects.

Salvia Officinalis (Sage) Oil

A 65-yr old healthy woman, a professional aromatherapist, with no prior history of skin disease, presented with eczema on her arms and upper trunk, which later spread to the legs, face, and hands.[53] The hand eczema became chronic and was associated with handling household cleansers, sealing wax and paints, as well as customary dilution of essential oils. The subject tested positive to a fragrance mix (++) in the European standard series, and to lemongrass oil (++), neroli oil (+), and peppermint oil (+), in a perfume series. When patch tested with personally-used essential oils, diluted in petrolatum at 1% and 5%, the subject tested positive to 17 out of 20 oils, of which *Salvia officinalis* was one (++, at both concentrations). The subject recalled lemongrass being the first oil she had used in aromatherapy, which the researchers surmised had induced primary sensitization, and lead to later development of dermatitis to the other essential oils.

SUMMARY

According to the *Dictionary*, various functions are reported for these 12 *Salvia officinalis* (sage)-derived ingredients as used in cosmetics, with skin-conditioning agent and fragrance ingredient being the most common. Other reported functions include as an antioxidant, oral care agent, flavoring agent, and exfoliant. Salvia Officinalis (Sage) Leaf Extract is reported to have the greatest frequency of use, in 213 formulations, more than half (116) are rinse-offs. The highest reported concentration of use amongst these ingredients is for Salvia Officinalis (Sage) Leaf Extract, at up to 0.38% in other skin preparations.

The acute dermal LD_{50} of Salvia Officinalis (Sage) Leaf Extract, eluted in 50% 1,3-butylene glycolic solution, was determined to be > 2000 mg/kg in 5 mice. The acute dermal LD_{50} of *Salvia officinalis* oil, or *Salvia officinalis* leaf oil (unclear from source), was determined to be > 5000 mg/kg in rabbits. Of 6 female Swiss mice administered a single oral dose of 5, 50, 500, or 5000 mg/kg bw hydroalcoholic *Salvia officinalis* extract, one mouse in the 5000 mg/group died; the acute oral LD_{50} was determined to be 44,760 mg/kg. No mortality or signs of toxicity were observed in 6 female albino rats dosed with up to 2000 mg/kg bw of an ethanolic *Salvia officinalis* leaf and stem extract; the extract was considered non-toxic at the maximum dose of 2000 mg/kg bw. Lethargy was observed in all groups of 10 male Wistar rats administered an undiluted oral dose of 1290, 2020, 3200, or 5000 mg/kg bw *Salvia officinalis* flower/leaf/stem water. One animal from the 1290 mg/kg group, 4 animals from the 2020 mg/kg group, 7 animals from the 3200 mg/kg group, and 9 animals from the 5000 mg/kg group died. The acute oral LD_{50} of *Salvia officinalis* oil or *Salvia officinalis* leaf oil in rats was determined to be 2600 mg/kg bw.

In an 8-wk study, white rats were administered a progressively increasing oral dose of *Salvia officinalis* oil (250, 500, 1000, or 1250 mg/kg bw/d), convulsions and mortality were observed with increasing dosage. The NOAEL was determined to be 250 mg/kg bw/d, under the study conditions.

A group of 7 female Wistar rats administered a 30-d oral dose of 30 mg/kg bw/d hydroalcoholic *Salvia officinalis* extract did not exhibit significant differences in hormone levels or estrous cycle lengths, as compared to controls administered distilled water. However, a significant increase in alveolar buds, lobules, and the diameter of mammary ducts was observed. Groups of 6 immature, ovariectomized rats orally dosed with 50, 100 or 200 mg/kg bw *Salvia officinalis* leaf and stem extract for 7 d exhibited significant increases in positive staining for estrogen receptors in the 100 mg/kg group. Serum levels of LH and FSH were also significantly lower (41.7% and 49.1%) in the 200 mg/kg group, compared to ovariectomized controls. In a reproductive toxicity study with 13 gravid female ICR mice, a 14-d diet containing 0.25% *Salvia officinalis* oil caused significant decreases in embryo cell distribution, according to nucleus number.

Salvia officinalis flower/leaf/stem extract and Salvia Officinalis (Sage) Leaf Extract were not found genotoxic when tested at doses up to 5000 µg/plate in bacterial mutation assays; *Salvia officinalis* oil was not genotoxic at up to 0.15 mg/ml in a chromosome aberration test. When tested at doses of up to 457 µg, *Salvia officinalis* oil significantly inhibited bacterial growth, however, was not genotoxic, in an Ames test. C3H mice intraperitoneally dosed with up to 100 µl/kg *Salvia officinalis* extract, after exposure to MMC, had a significant decrease in the frequency of cells in metaphase with chromosome aberrations. The 100 µl/kg dose of *Salvia officinalis* extract exhibited cytotoxicity, even in the absence of MMC.

Twenty female Wistar rats, that were induced with dimethyl-benzanthracene to develop breast cancer, saw significant reductions in cancerous lobules during the fourth and sixth month of being orally dosed with *Salvia officinalis* leaf extract for 6 mo, compared to sunflower oil controls. *Salvia officinalis* leaf oil yielded IC_{50} values of 554.5 ± 1.5 µg/ml, 394.6 ± 1.4 µg/ml, and 207.5 ± 0.8 µg/ml against breast cancer, colon cancer, and murine macrophage cell lines, respectively. *Salvia officinalis* oil was determined to have an IC_{50} of 367.45 ± 1.5 µg/ml and 108.70 ± 1.2 µg/ml against C32 human melanoma and ACHN renal carcinoma cell lines, respectively.

A 50 µl dose of undiluted *Salvia officinalis* flower/leaf/stem water did not cause irritation in an in vitro Rhe test. In another in vitro Rhe test, the mean percent cell viability of tissues treated with 16 µl of undiluted *Salvia officinalis* flower/leaf/stem water was 2.1%, compared to 2.9% in positive controls exposed to 5% sodium dodecyl sulfate; the test substance was classified as a skin irritant or dermally corrosive. Undiluted and 10% Salvia Officinalis (Sage) Leaf Extract, eluted in 50% 1,3-butylene glycolic solution, were not irritating to rabbit skin. Undiluted *Salvia officinalis* oil, or *Salvia officinalis* leaf oil, was moderately irritating when applied to intact and abraded rabbit skin under occlusion for 24 h. One

irritation reaction occurred in a 24-h patch test of undiluted *Salvia officinalis* oil, or leaf oil, using 20 subjects. The sensitization potential of a product containing 0.005% Salvia Officinalis (Sage) Leaf Extract, tested at a 1% dilution in distilled water and of a body lotion containing 0.03% Salvia Officinalis (Sage) Oil was tested in 2 separate occlusive HRIPTs completed in 53 subjects; no adverse reactions were observed, and the test substances were deemed non-irritating and non-sensitizing. No irritation or sensitization was observed when 8% *Salvia officinalis* oil, or leaf oil, in petrolatum was tested via a 48-h occlusive patch test or a maximization test, respectively. *Salvia officinalis* flower/leaf/stem water was not considered an ocular irritant when tested at a dose of 50 µl in an EpiOcular™ model.

An 85-yr old woman had positive reactions in a patch test to a lip balm containing *Salvia officinalis* extract, and to 2 of the manufacturer-supplied ingredients, *Salvia officinalis* extract and polygonum, patched separately in water and petrolatum. Patch results for the lip balm, *Salvia officinalis* extract, and polygonum were negative in 20 other subjects. A 65-yr old woman, with no prior skin disease, presented with eczema on her arms, upper trunk, legs, face, and hands; when patch tested with personally-used essential oils diluted in petrolatum, the subject tested positive to *Salvia officinalis* oil at 1% and 5%. Primary sensitization was attributed to lemongrass oil, and subsequent dermatitis to the frequent use of other essential oils as an aromatherapist.

DRAFT DISCUSSION

[Note: This Discussion is in draft form, and changes may be made following the Panel meeting.]

This assessment reviews the safety of 12 *Salvia officinalis* (sage)-derived ingredients as used in cosmetic formulations. The Panel concluded [TBD].

The Panel noted the GRAS status and historical food uses of *Salvia officinalis* (sage)-derived ingredients, especially *Salvia officinalis* leaves, and agreed that systemic exposures from food would be much higher than those from cosmetic use. Additionally, the Panel was reassured by the 250 mg/kg/d NOAEL seen in an 8-wk study of rats orally dosed with *Salvia officinalis* oil. The Panel reasoned that *Salvia officinalis* leaves are the main plant part used to manufacture *Salvia officinalis* oil, *Salvia officinalis* leaf oil, and *Salvia officinalis* leaf extract, which are the most constituent-rich ingredients, and therefore would contain the highest levels of potential sensitizers.

The Panel also expressed concern about pesticide residues, heavy metals, and other plant species that may be present in botanical ingredients. For these *Salvia officinalis*-derived ingredients, the Panel acknowledged the presence of thujone, a potential neurotoxicant, and terpenes/terpenoids, which have the highest potential to cause dermal sensitization; however, it was agreed that the concentrations of these components in cosmetic formulations would be very low. Nonetheless, the Panel emphasized that the cosmetics industry should continue to use current good manufacturing practices (cGMPs) to limit impurities.

The Panel discussed the issue of incidental inhalation exposure resulting from these ingredients (e.g., Salvia Officinalis (Sage) Leaf Oil is used at up to 0.012% in pump spray suntan formulations and up to 0.0011% in underarm deodorant spray). Inhalation toxicity data were not available. However, the Panel noted that in aerosol products, 95% – 99% of droplets/particles would not be respirable to any appreciable amount. Furthermore, droplets/particles deposited in the nasopharyngeal or bronchial regions of the respiratory tract present no toxicological concerns based on the chemical and biological properties of these ingredients. Coupled with the small actual exposure in the breathing zone and the concentrations at which the ingredients are used, the available information indicates that incidental inhalation would not be a significant route of exposure that might lead to local respiratory or systemic effects. A detailed discussion and summary of the Panel's approach to evaluating incidental inhalation exposures to ingredients in cosmetic products is available at https://www.cir-safety.org/cir-findings.

CONCLUSION

To be determined.

TABLES

Table 1: Definitions and functions of *Salvia officinalis* (sage)-derived ingredients[1]

Ingredient/CAS No.	Definition	Function
Salvia Officinalis (Sage) Extract 84082-79-1 (generic)	Salvia Officinalis (Sage) Extract is the extract of the whole plant, *Salvia officinalis*.	Skin-conditioning agents-miscellaneous
Salvia Officinalis (Sage) Flower/Leaf/Stem Extract 84082-79-1 (generic)	Salvia Officinalis (Sage) Flower/Leaf/Stem Extract is the extract of the flowers, leaves, and stems of *Salvia officinalis*.	Fragrance ingredients; Skin-conditioning agents - miscellaneous
Salvia Officinalis (Sage) Flower/Leaf/Stem Juice 84082-79-1 (generic)	Salvia Officinalis (Sage) Flower/Leaf/Stem Juice is the juice expressed from the flowers, leaves, and stems of *Salvia officinalis*.	Antioxidants
Salvia Officinalis (Sage) Flower/Leaf/Stem Water 84082-79-1 (generic)	Salvia Officinalis (Sage) Flower/Leaf/Stem Water is the aqueous solution of the steam distillate obtained from the flowers, leaves, and stems of *Salvia officinalis*.	Fragrance ingredients
Salvia Officinalis (Sage) Leaf 84082-79-1 (generic)	Salvia Officinalis (Sage) Leaf are the leaves of *Salvia officinalis*.	not reported
Salvia Officinalis (Sage) Leaf Extract 84082-79-1 (generic)	Salvia Officinalis (Sage) Leaf Extract is the extract of the leaves of *Salvia officinalis*.	Oral care agents; Skin-conditioning agents-miscellaneous
Salvia Officinalis (Sage) Leaf Oil 8022-56-8 (generic) 84776-73-8 (generic)	Salvia Officinalis (Sage) Leaf Oil is the volatile oil obtained from the leaves of *Salvia officinalis*.	Flavoring agents; Fragrance ingredients; Skin-conditioning agents - miscellaneous
Salvia Officinalis (Sage) Leaf Powder 84082-79-1 (generic)	Salvia Officinalis (Sage) Leaf Powder is the powder obtained from the dried ground leaves of *Salvia officinalis*.	Exfoliants
Salvia Officinalis (Sage) Leaf Water 84082-79-1 (generic)	Salvia Officinalis (Sage) Water is an aqueous solution of the steam distillate obtained from the leaves of *Salvia officinalis*.	Fragrance ingredients; Skin-conditioning agents - miscellaneous
Salvia Officinalis (Sage) Oil 8022-56-8 (generic) 84776-73-8 (generic)	Salvia Officinalis (Sage) Oil is the essential oil derived from the herbal plant, *Salvia officinalis*.	Fragrance ingredients; Skin-conditioning agents-miscellaneous
Salvia Officinalis (Sage) Root Extract 84082-79-1 (generic)	Salvia Officinalis (Sage) Root Extract is the extract of the roots of *Salvia officinalis*.	Skin-conditioning agents-miscellaneous
Salvia Officinalis (Sage) Water 84082-79-1 (generic)	Salvia Officinalis (Sage) Water is an aqueous solution of the steam distillate obtained from *Salvia officinalis.*	Fragrance ingredients

Table 2. Chemical properties of *Salvia officinalis* (sage) – derived ingredients

Property	Value	Reference
	Salvia Officinalis (Sage) Flower/Leaf/Stem Water	
Physical Form	Liquid	4
Color	Light yellow to yellow	4
Odor	Camphoraceous, herbal, spicy, floral, pine, thujone-like	54
Relative Density (@ 20 ºC)	0.9153	4
Boiling Point (ºC @ 1013 kPa)	189.3	4
	Salvia Officinalis (Sage) Leaf Extract	
Physical Form	Liquid	15
Color	Medium to dark amber	15
Refractive Index (@ 25 °C)	1.320 – 1.3450	15
Specific Gravity (@ 25 °C)	0.99 – 1.02	15
pH (@ 25 °C)	4 – 7	15
Solubility	In water	15
	Salvia Officinalis (Sage) Leaf Water	
Physical Form	Liquid	14
Color	colorless	14
Density (g/cm^3 @ 20°C)	0.999 – 1.002	14
Refractive Index	1.332 – 1.339	14
Miscibility	In water and 50% v/v alcohol	14
Non-miscibility	Mineral and vegetal oils	14
pH	4 – 6.5	14

Table 3. Composition of *Salvia officinalis* oils

	Salvia officinalis leaf oil* [26]	Salvia officinalis oil* [17]
Compound	**Percentage (%)**	
cis-salvene	--	0.40
(*Z*)-salvene	0.2	--
(*E*)-salvene	trace	--
tricyclene	0.2	0.09
α-thujene	0.3	**13.9**
α-pinene	5.0	**12.91**
camphene	5.2	4.74
sabinene	0.1	--
trans-sabinene hydrate	--	0.13
β-pinene	4.1	5.93
β-thujene	--	8.91
1-octen-3-ol	trace	--
β-myrcene	--	0.69
myrcene	2.8	--
α-phellandrene	0.1	--
1-phellandrene	--	0.15
α-terpinene	0.5	0.31
α-terpinolene	--	0.20
p-cymene	0.6	--
limonene	1.5	--
1-napthalenepropanol	--	0.11
1,8-cineole	**26.9**	**22.91**
(*Z*)-β-ocimene	0.1	0.1
γ-terpinene	0.7	0.41
cis-sabinene hydrate	0.1	--
terpinolene	0.2	--
p-cymenene	trace	--
linalool	0.3	--
α- thujone	**17.2**	--
β- thujone	3.8	--
chrysanthenone	trace	--
3-*iso*-thujanol	trace	--
camphor	**12.8**	3.28
neo-*iso*-*3*-thujanol	trace	--
trans-pinocamphone	0.1	--
3- thujanol	0.2	--
borneol	1.2	6.18
δ- terpineol	0.4	--
terpinen-4-ol	0.5	--
α- gurjunene	--	0.1
α- terpineol	1.1	--
linalyl acetate	0.2	--
endobornyl acetate	--	0.77
bornyl acetate	1.1	0.39
trans-sabinyl acetate	0.1	--
trans-caryophyllene		7.41
2,3- pinanediol	trace	--
α- terpinyl acetate	0.6	--
α- copaene	0.1	--
β- caryophyllene	4.9	--
6-oxobornyl acetate	trace	--
α- maaliene	0.1	--
aromadendrene	0.4	0.56
myltayl-4 (12)-ene	trace	--
5-oxobornyl acetate	0.1	--
α- humulene	3.1	3.19
9-*epi*-β- caryophyllene	0.1	--
trans-cadina 1(6)-4-diene	0.1	--
guaia-1(10)-11- diene	0.1	--
viridiflorene	0.3	--
δ- amorphene	0.1	--
δ- cadinene	0.1	0.24
Caryophyllene oxide	0.1	--
viridiflorol	2.0	3.08
humulene epoxide II	0.2	--
carylophylla-4(12),8(13)-dien-5α-ol	0.1	--

Table 3. Composition of *Salvia officinalis* oils

	Salvia officinalis leaf oil* [26]	Salvia officinalis oil* [17]
Compound	**Percentage (%)**	
manool	0.2	--

Principal compounds, e.g. compounds for which the concentrations exceeded 10%, are **bolded.**
[a] -- indicates not reported.
* measured via gas chromatography- mass spectrometry

Table 4. Frequency (2021)[27] and concentration of use (2020)[28,29] according to duration and exposure

	# of Uses	Max Conc of Use (%)	# of Uses	Max Conc of Use (%)	# of Uses	Max Conc of Use (%)
	Salvia Officinalis (Sage) Extract		**Salvia Officinalis (Sage) Leaf**		**Salvia Officinalis (Sage) Leaf Extract**	
Totals*	**66**	**0.000028-0.078**	**1**	**0.0001-0.1**	**213**	**0.000004-0.38**
Duration of Use						
Leave-On	*41*	*0.001-0.078*	*1*	*0.0001*	94	*0.0001-0.38*
Rinse-Off	*25*	*0.000028-0.01*	*NR*	*0.1*	116	*0.000004-0.08*
Diluted for (Bath) Use	*NR*	*NR*	*NR*	*NR*	3	*0.004*
Exposure Type						
Eye Area	NR	NR	NR	0.0001	4	NR
Incidental Ingestion	3	NR	NR	NR	4	NR
Incidental Inhalation-Spray	15[a]; 17[b]	NR	NR	NR	1; 43[a]; 26[b]	0.0001-0.002; 0.001-0.018[a]
Incidental Inhalation-Powder	17[b]	0.02[c]	NR	NR	26[b]	NR
Dermal Contact	32	0.001-0.078	1	0.0001-0.1	131	0.0002-0.38
Deodorant (underarm)	1[a]	Not spray: 0.001% Spray: 0.0011%	NR	NR	4[a]	NR
Hair - Non-Coloring	30	0.000028-0.003	NR	NR	61	0.000004-0.08
Hair-Coloring	1	NR	NR	NR	17	NR
Nail	NR	NR	NR	NR	NR	NR
Mucous Membrane	4	0.0035-0.01	NR	NR	36	0.004-0.01
Baby Products	NR	NR	NR	NR	NR	NR
	Salvia Officinalis (Sage) Leaf Oil		**Salvia Officinalis (Sage) Leaf Water**		**Salvia Officinalis (Sage) Oil**	
Totals*	**2**	**0.0028-0.02**	**3**	**0.00071**	**87**	**0.000097-0.22**
Duration of Use						
Leave-On	*NR*	*0.0028-0.02*	2	*0.00071*	56	*0.012-0.22*
Rinse Off	*1*	*0.02*	1	*NR*	25	*0.000097-0.18*
Diluted for (Bath) Use	*1*	*NR*	NR	*NR*	6	*NR*
Exposure Type						
Eye Area	NR	NR	NR	NR	1	NR
Incidental Ingestion	1	NR	NR	NR	2	0.005-0.011
Incidental Inhalation-Spray	NR	0.012	1[a]	0.00071[b]	1; 22[a]; 11[b]	0.005[a]
Incidental Inhalation-Powder	NR	NR	NR	0.00071[b]	11[b]	0.22[c]
Dermal Contact	1	0.0028-0.02	3	0.00071	74	0.0097-0.22
Deodorant (underarm)	NR	NR	1[a]	NR	2[a]	NR
Hair - Non-Coloring	NR	NR	NR	NR	11	0.000097-0.0049
Hair-Coloring	NR	NR	NR	NR	NR	NR
Nail	NR	NR	NR	NR	NR	NR
Mucous Membrane	2	NR	NR	NR	10	0.005-0.02
Baby Products	NR	NR	NR	NR	NR	NR
	Salvia Officinalis (Sage) Water					
Totals*	**1**	**NR**				
Duration of Use						
Leave-On	*1*	*NR*				
Rinse-Off	*NR*	*NR*				
Diluted for (Bath) Use	*NR*	*NR*				
Exposure Type						
Eye Area	NR	NR				
Incidental Ingestion	NR	NR				
Incidental Inhalation-Spray	1[b]	NR				
Incidental Inhalation-Powder	1[b]	NR				
Dermal Contact	1	NR				
Deodorant (underarm)	NR	NR				
Hair - Non-Coloring	NR	NR				
Hair-Coloring	NR	NR				
Nail	NR	NR				
Mucous Membrane	NR	NR				
Baby Products	NR	NR				

*Because each ingredient may be used in cosmetics with multiple exposure types, the sum of all exposure types may not equal the sum of total uses.
[a] It is possible these products are sprays, but it is not specified whether the reported uses are sprays.
[b] Not specified whether a spray or a powder, but it is possible the use can be as a spray or a powder, therefore the information is captured in both categories.
[c] It is possible these products are powders, but it is not specified whether the reported uses are powders.
NR – no reported use

Table 5. *Salvia officinalis* (sage) - derived ingredients not reported to be in use

Salvia Officinalis (Sage) Flower/Leaf/Stem Extract
Salvia Officinalis (Sage) Flower/Leaf/Stem Juice
Salvia Officinalis (Sage) Flower/Leaf/Stem Water
Salvia Officinalis (Sage) Leaf Powder
Salvia Officinalis (Sage) Root Extract

Table 6. Genotoxicity studies

Test Article	Concentration/Dose	Vehicle	Test System	Procedure	Results	Reference
			IN VITRO			
Salvia officinalis flower/leaf/stem water	Up to 5000 µg/plate; with and without metabolic activation	Paraffin oil	*S. typhimurium* strains TA 98, TA 100, TA 1535, TA 1537, and *E. coli* WP2	Bacterial reverse mutation assay, in accordance with OECD TG 471.	Not genotoxic	[4]
Salvia Officinalis Leaf Extract (50 vol% 1,3-butylene glycolic solution)	5000 µg/0.1 ml/plate	none specified	*Salmonella typhimurium* strains TA 98, TA 100, TA 1535, and TA1537 and *Escherichia coli* WP2uvrA	Bacterial reverse mutation assay	Not genotoxic	[16]
Salvia officinalis oil	91, 183, or 457 µg, with and without metabolic activation	DMSO	*S. typhimurium* strains TA 98 and TA 100	Ames test	Not genotoxic. Significantly inhibited bacterial growth.	[44]
Salvia officinalis oil	0.25, 0.5, or 1 µl/plate	DMSO	*S. typhimurium* strains TA 98, TA 100, TA 1535, TA1537	Bacterial reverse mutation assay	Not genotoxic	[42]
Salvia officinalis oil	Up to 0.15 mg/ml	Ethanol	*S. typhimurium* strains TA92, TA 94, TA 98, TA 100, TA 1535, TA 1537	Chromosomal aberration test	Not genotoxic	[43]

DMSO- dimethyl sulfoxide

REFERENCES

1. Nikitakis J, Kowcz A. Web-Based *International Cosmetic Ingredient Dictionary and Handbook* (wINCI *Dictionary*). http://webdictionary.personalcarecouncil.org/jsp/IngredientSearchPage.jsp. Washington, D.C.: Personal Care Products Council. Last Updated: 2021. Accessed: 10/21/2021.

2. Millet Y, Jouglard J, Steinmetz MD, Tognetti P, Joanny P, Arditti J. Toxicity of some essential plant oils. Clinical and experimental study. *Clin Toxicol* 1981;18(12):1485-1498.

3. Karlberg At, Lepoittevin JP. One hundred years of allergic contact dermatitis due to oxidized terpenes: What we can learn from old research on turpentine allergy. *Contact Dermatitis* 2021.

4. European Chemical Agency (ECHA). REACH registration dossier: Sage, *Salvia officinalis*, ext. (CAS 84082-79-1). https://echa.europa.eu/registration-dossier/-/registered-dossier/25026/1. Last Updated: 2018. Accessed: 06/30/2020.

5. European Medicines Agency. Assessment report on *Salvia officinalis L.*, *folium* and *Salvia officinalis L.*, *aetheroleum*. 2016. https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-salvia-officinalis-l-folium-salvia-officinalis-l-aetheroleum-revision-1_en.pdf. Accessed 06/29/2020.

6. European Medicines Agency. European Union herbal monograph on *Salvia officinalis* L., folium. 2016. https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-salvia-officinalis-l-folium-revision-1_en.pdf. Accessed 06/29/2020.

7. Jakovljević M, Jokic S, Molnar M, et al. Bioactive profile of various *Salvia officinalis L.* preparations. *Plants (Basel)* 2019;8(3):55.

8. Ghorbani A, Esmaeilizadeh M. Pharmacological properties of *Salvia officinalis* and its components. *J Tradit Complement Med* 2017;7(4):433-440.

9. Sharma Y, Fagan J, Schaefer J. Ethnobotany, phytochemistry, cultivation and medicinal properties of Garden sage (*Salvia officinalis L.*). *J Pharmacogn Phytochem* 2019;8:3139-3148.

10. Solabia. 2009. Specifications data sheet Glycolysat of Sage UP (Salvia Officinalis (Sage) Leaf Extract). (Unpublished data submitted by the Personal Care Products Council on April 1, 2021.)

11. Walch SG, Tinzoh LN, Zimmermann BF, Stühlinger W, Lachenmeier DW. Antioxidant capacity and polyphenolic composition as quality indicators for aqueous infusions of *Salvia officinalis L.* (sage tea). *Front Pharmacol* 2011;2:79.

12. Gericke S, Lübken T, Wolf D, Kaiser M, Hannig C, Speer K. Identification of new compounds from sage flowers (*Salvia officinalis L.*) as markers for quality control and the influence of the manufacturing technology on the chemical composition and antibacterial activity of sage flower extracts. *J Agric Food Chem* 2018;66(8):1843-1853.

13. Martins N, Barros L, Santos-Buelga C, Henriques M, Silva S, Ferreira IC. Evaluation of bioactive properties and phenolic compounds in different extracts prepared from *Salvia officinalis L*. *Food Chem* 2015;170:378-385.

14. Solabia. 2009. Specifications data sheet Vegebios of Sage 1.5P (Salvia Officinalis (Sage) Leaf Water). (Unpublished data submitted by the Personal Care Products Council on April, 2021.)

15. Anonymous. 2020. Salvia Officinalis (Sage) Leaf Extract (method of manufacture, impurities and specifications). (Unpublished data submitted by Personal Care Products Council on December 10, 2020.)

16. Anonymous. 2021. Summary Information Salvia Officinalis (Sage) Leaf Extract. (Unpublished data submitted by Personal Care Products Council on January 5, 2021.)

17. Mehdizadeh T, Hashemzadeh M, Nazarizadeh A, et al. Chemical composition and antibacterial properties of *Ocimum basilicum*, *Salvia officinalis* and *Trachyspermum ammi* essential oils alone and in combination with nisin. *Res J Pharmacogn* 2016;3(4):51-58.

18. Stojanovic D, Lakušić B, Ristić M, Slavkovska V, Lakusic D. Variations in essential oil yields and compositions of *Salvia officinalis* (*Lamiaceae*) at different developmental stages. *Bot Serb* 2013;37:127-139.

19. Tober C, Schoop R. Modulation of neurological pathways by *Salvia officinalis* and its dependence on manufacturing process and plant parts used. *BMC Complement Altern Med* 2019;19(1):128.

20. Baranauskiene R, Dambrauskienė E, Venskutonis R, Viskelis P. 2011. Influence of harvesting time on the yield and chemical composition of sage (*Salvia officinalis L.*). Kaunas, Lithuania. 104-109. (Conference proceedings presented at FoodBalt, May 5-6, 2011.)

21. Arraiza M, Arrabal C, López JV. Seasonal Variation of Essential Oil Yield and Composition of Sage (*Salvia officinalis L.*) Grown in Castilla - La Mancha (Central Spain). *Notulae Botanicae Horti Agrobotanici Cluj-Napoca* 2012;40:106-108.

22. Brancato A, Brocca D, Lentdecker C, et al. Modification of the existing maximum residue levels for ametoctradin in herbs and edible flowers. *EFSA J* 2017;15(9).

23. European Food Safety Authority (EFSA). Reasoned opinion on the modification of the existing MRLs for ametoctradin in sage and basil. *EFSA J* 2015;13(6):4153.

24. Szpyrka E, Słowik-Borowiec M. Consumer health risk to pesticide residues in *Salvia officinalis L.* and its infusions. *J Environ Sci Health B* 2019;54(1):14-19.

25. Afonso AF, Pereira OR, Fernandes Â, et al. Phytochemical composition and bioactive effects of *Salvia africana*, *Salvia officinalis* 'Icterina' and *Salvia mexicana* aqueous extracts. *Molecules* 2019;24(23):4327.

26. Craft JD, Satyal P, Setzer WN. The Chemotaxonomy of common sage (*Salvia officinalis*) based on the volatile constituents. *Medicines (Basel)* 2017;4(3):47.

27. U.S. Food and Drug Administration Center for Food Safety & Applied Nutrition (CFSAN). Voluntary Cosmetic Registration Program - Frequency of Use of Cosmetic Ingredients. College Park, MD. 2021. (Obtained under the Freedom of Information Act from CFSAN; requested as "Frequency of Use Data" January 4, 2021; received January 21, 2021.)

28. Personal Care Products Council. 2020. Concentration of Use by FDA Product Category: Sage-Derived Ingredients. (Unpublished data submitted by Personal Care Products Council on February 26, 2020.)

29. Personal Care Products Council. 2020. Concentration of Use by FDA Product Category: Salvia Officinalis (Sage) Leaf Oil. (Unpublished data submitted by Personal Care Products Council on October 27, 2020.)

30. Johnsen MA. The Influence of Particle Size. *Spray Technology and Marketing* 2004;14(11):24-27.

31. Rothe H. 2011. Special aspects of cosmetic spray safety evaluations: Principles on inhalation risk assessment. (Unpublished data presented at the 26 September Expert Panel meeting. Washington D.C.)

32. Bremmer HJ, Prud'homme de Lodder LCH, van Engelen JGM. Cosmetics Fact Sheet: To assess the risks for the consumer; Updated version for ConsExpo 4. Bilthoven, Netherlands: Netherlands National Institute for Public Health and the Environment;2006. RIVM 320104001/2006. http://www.rivm.nl/bibliotheek/rapporten/320104001.pdf. Accessed 8/24/2011. Pages1-77.

33. Rothe H, Fautz R, Gerber E, et al. Special aspects of cosmetic spray safety evaluations: Principles on inhalation risk assessment. *Toxicol Lett* 2011;205(2):97-104.

34. European Commission. CosIng database; following Cosmetic Regulation No. 1223/2009 https://ec.europa.eu/health/sites/health/files/endocrine_disruptors/docs/cosmetic_1223_2009_regulation_en.pdf. Last Updated: 2020. Accessed: 04/14/2020.

35. International Fragrance Association (IFRA). IFRA Standard 49th Amendment: Thujone. https://ifrafragrance.org/standards/IFRA_STD_102.pdf. Last Updated: 01/10/2020. Accessed: 07/14/2020.

36. Research Institute for Fragrance Materials (RIFM). Sage Oil, Dalmatian. In: Opdyke DLJ, ed. *Monographs on Fragrance Raw Materials: A Collection of Monographs Originally Appearing in Food and Cosmetics Toxicology. .* Pergamon Press; 1979: 672.

37. Grdiša M, Jug-Dujaković M, Lončarić M, et al. Dalmatian Sage (*Salvia officinalis L.*): A review of biochemical contents, medical properties and genetic diversity. *Agric Conspec Sci* 2015;80(2):69-78.

38. Rodrigues MRA, Kanazawa LKS, das Neves TLM, et al. Antinociceptive and anti-inflammatory potential of extract and isolated compounds from the leaves of *Salvia officinalis* in mice. *J Ethnopharmacol* 2012;139(2):519-526.

39. Sabry MM, Abdel-Rahman RF, El-Shenawy SM, Hassan AM, El-Gayed SH. Estrogenic activity of Sage (*Salvia officinalis L.*) aerial parts and its isolated ferulic acid in immature ovariectomized female rats. *J Ethnopharmacol* 2022;282:114579.

40. Monsefi M, Abedian M, Azarbahram Z, Ashraf MJ. *Salvia officinalis L.* induces alveolar bud growing in adult female rat mammary glands. *Avicenna J Phytomed* 2015;5(6):560-567.

41. Domaracký M, Rehák P, Juhás Š, Koppel J. Effects of selected plant essential oils on the growth and development of mouse preimplantation embryos in vivo. *Physiol Res* 2007;56(1):97-104.

42. Zani F, Massimo G, Benvenuti S, et al. Studies on the genotoxic properties of essential oils with *Bacillus subtilis* rec-assay and *Salmonella*/microsome reversion assay. *Planta Med* 1991;57(3):237-241.

43. Ishidate M, Jr., Sofuni T, Yoshikawa K, et al. Primary mutagenicity screening of food additives currently used in Japan. *Food Chem Toxicol* 1984;22(8):623-636.

44. De Martino L, De Feo V, Nazzaro F. Chemical composition and in vitro antimicrobial and mutagenic activities of seven *Lamiaceae* essential oils. *Molecules* 2009;14(10):4213-4230.

45. Vujosevic M, Blagojević J. Antimutagenic effects of extracts from sage *(Salvia officinalis*) in mammalian system in vivo. *Acta Vet Hung* 2004;52(4):439-443.

46. Zare H. Effects of *Salvia officinalis* extract on the breast cancer cell line. *Sci Med Journ* 2019;1(1):25-29.

47. Río ÁGd, Sanz J, Coloma AG, et al. Cytotoxic activity of ±-humulene and transcaryo- phyllene from *Salvia officinalis* in animal and human tumor cells. *An R Acad Nac Farm* 2010;76(3):343-356.

48. Loizzo M, Tundis R, Menichini F, Saab A, Statti G, Menichini F. Cytotoxic activity of essential oils from *Labiatae* and *Lauraceae* families against in vitro human tumor models. *Anticancer Res* 2007;27(5A):3293-3299.

49. Tisserand R, Young R. *Essential Oil Safety: A Guide for Health Care Professionals.* 2nd ed. Edinburgh, United Kingdom: Churchill Livingston, Elsevier; 2014.

50. Anonymous. 2017. Clinical safety evaluation repeated insult patch test (product contains 0.005% Salvia Officinalis (Sage) Leaf Extract (1% dilution tested)). (Unpublished data submitted by the Personal Care Products Council on April 29, 2021.)

51. Anonymous. 2000. Repeated insult patch test (body lotion containing 0.03% Salvia Officinalis (Sage) Oil. (Unpublished data submitted by the Personal Care Products Council on April 29, 2021.)

52. Mayer E, Gescheidt-Shoshany H, Weltfriend S. Allergic contact dermatitis caused by *Salvia officinalis* extract. *Contact Dermatitis* 2011;64(4):237-238.

53. Selvaag E, Holm JO, Thune P. Allergic contact dermatitis in an aroma therapist with multiple sensitizations to essential oils. *Contact Dermatitis* 1995;33(5):354-355.

54. Jirovetz L, Buchbauer G, Denkova Z, Slavchev A, Stoyanova A, Schmidt E. Chemical composition, antimicrobial activities and odor descriptions of various Salvia sp. and Thuja sp. essential oils. *Nutrition-Vienna-* 2006;30(4):152.

Personal Care Products Council
Committed to Safety, Quality & Innovation

Memorandum

TO: Bart Heldreth, Ph.D.
Executive Director - Cosmetic Ingredient Review

FROM: Carol Eisenmann, Ph.D.
Personal Care Products Council

DATE: April 1, 2021

SUBJECT: Salvia Officinalis (Sage) Leaf Water and Salvia Officinalis (Sage) Leaf Extract

Solabia. 2009. Specifications data sheet Vegebios of Sage 1.5P (Salvia Officinalis (Sage) Leaf Water).

Solabia. 2009. Specifications data sheet Glycolysat of Sage UP (Salvia Officinalis (Sage) Leaf Extract).

SPECIFICATIONS DATA SHEET

Vegebios® of Sage 1.5P

Ref. FV501

DEFINITION

Vegebios® of Sage 1.5P is an aqueous extract obtained by steam distillation of the leaves of sage (*Salvia officinalis*).

PRESENTATION

• **Sample**	plastic flask - 125 mL
• **Code / Packaging** *to be mentioned with your order*	FV501KC – can 5 kg FV501KE – can 20 kg

ORGANOLEPTIC CHARACTERISTICS

• **Appearance**	transparent liquid
• **Color**	colorless
• **Odor**	characteristic

ANALYTICAL CHARACTERISTICS

• **pH**	4.0 – 6.5
• **Refractive index at 20°C** MODIFICATION	1.332 - 1.339
• **Density at 20°C**	0.999 - 1.002

MICROBIOLOGICAL CHARACTERISTICS

• **Total aerobic mesophilic micro-organisms** *according USP*	≤ 100 C.F.U./g

. Vegebios® of Sage 1.5P

Additional Analysis

- **Identification of essential oils** borneol
  TLC
- **Allergenic substances study**: a bibliographical study on *Salvia officinalis* revealed the potential presence of geraniol, limonene and linalool in the plant. A theoretical calculation allows to establish that their content in Vegebios® of Sage 1.5P was less than 10 ppm for geraniol, less than 125 ppm for limonene and less than 225 ppm for linalool. The other allergenic substances as listed in the 7th amendment of the European Cosmetic Directive have not been found in the plant bibliography.

Solubilities (10% diluted)

- **Water** miscible
- **Alcohol 50% v/v** miscible
- **Mineral oils** non miscible
- **Vegetal oils** non miscible

Storage

- **Shelf life** 3 years in closed original packaging
- **Preservative system** 1.5% of phenoxyethanol
- **Storage conditions** store at room temperature

Legislative Information

- **INCI** Salvia officinalis water
- **CTFA** Modification Salvia officinalis (sage) leaf water
- **CAS** 84082-79-1
- **EINECS** 282-025-9
- **Other regulation status** authorized in Japan

Produced & Commercialized by CEP - SOLABIA Group
29 Rue Delizy – 93698 Pantin Cedex France
Tel 33 (0)1 48 10 19 40 – Fax 33 (0)1 48 91 18 77 - www.solabia.com

SPECIFICATIONS DATA SHEET

Glycolysat® of Sage UP

Ref. FG523

DEFINITION

Glycolysat® of Sage UP is a hydroglycolic extract obtained from the leaves of sage (*Salvia officinalis*). It is obtained by controlled extraction using propylene glycol and water.

PRESENTATION

• **Sample**	plastic flask - 125 mL
• **Code / Packaging** *to be mentioned with your order*	FG523KC - can 5 kg FG523KE - can 20 kg

ORGANOLEPTIC CHARACTERISTICS

• **Appearance**	translucent liquid with possibly a slight precipitate
• **Color** Modification	brown to brown orange
• **Odor**	characteristic

ANALYTICAL CHARACTERISTICS

• **pH**	4.0 – 5.0
• **Refractive index at 20°C**	1.410 – 1.420
• **Density at 20°C**	1.045 – 1.058
• **Dry extract** Modification *3g under halogen, 1 hour at 110°C*	1.8% – 3.0%

MICROBIOLOGICAL CHARACTERISTICS

• **Total aerobic mesophilic micro-organisms** *according USP*	≤ 100 C.F.U./g

Glycolysat® of Sage UP

ADDITIONAL ANALYSIS

- **Identification of essential oils** — borneol, cineol
  TLC
- **Identification des flavonoids** — luteolin, apigenin
  TLC
- **Identification of polyphenols** — caffeic acid, rosmarinic acid
  TLC
- **Allergenic substances study :** a bibliographical study on *Salvia officinalis* revealed the potential presence of geraniol, limonene and linalool in the plant. A theoretical calculation allows to establish that their content in Glycolysat® of Sage was less than 10 ppm for geraniol, less than 125 ppm for limonene and less than 225 ppm for linalool. The other allergenic substances as listed in the 7th amendment of the European Cosmetic Directive have not been found in the bibliography of the leaves of sage.

SOLUBILITIES (10% DILUTED)

Water	miscible	**Mineral oils**	non miscible
Alcohol 50% v/v	miscible	**Vegetal oils**	non miscible

STORAGE AND USE

- **Shelf life** — 3 years in closed original packaging
- **Preservative system** — preservative free
- **Storage conditions** — store at room temperature
- **Use conditions** — mix before use if necessary

LEGISLATIVE INFORMATION

- **INCI** — Propylene glycol / Aqua / Salvia officinalis extract
- **CTFA** — Propylene glycol (and) Water (and) Salvia officinalis (sage) leaf extract
- **CAS**

Propylene glycol	57-55-6
Aqua	7732-18-5
Salvia officinalis extract	84082-79-1

- **EINECS**

Propylene glycol	200-338-0
Aqua	231-791-2
Salvia officinalis extract	282-025-9

- **Other regulation status** — authorized in Japan

Produced & Commercialized by CEP - SOLABIA Group
29 Rue Delizy – 93698 Pantin Cedex France
Tel 33 (0)1 48 10 19 40 – Fax 33 (0)1 48 91 18 77 - www.solabia.com

Personal Care Products Council
Committed to Safety, Quality & Innovation

Memorandum

TO: Bart Heldreth, Ph.D.
Executive Director - Cosmetic Ingredient Review

FROM: Carol Eisenmann, Ph.D.
Personal Care Products Council

DATE: April 29, 2021

SUBJECT: Salvia Officinalis (Sage) Oil and Salvia Officinalis (Sage) Leaf Extract

Anonymous. 2000. Repeated insult patch test (body lotion containing 0.03% Salvia Officinalis (Sage) Oil.

Anonymous. 2017. Clinical safety evaluation repeated insult patch test (product contains 0.005% Salvia Officinalis (Sage) Leaf Extract (1% dilution tested)).

[redacted]

FINAL REPORT

CLINICAL SAFETY EVALUATION

REPEATED INSULT PATCH TEST

[redacted]

Body lotion containing 0.03%
Salvia Officinalis (Sage) Oil

Sponsor

[redacted]

Sponsor Representatives

[redacted]

Clinical Testing Facility

[redacted]

Sponsor Code: [redacted]
Panel No.: [redacted]
Entry No.:

Date of Final Report

2-1-00

[redacted]

[redacted] Panel No.:
Entry No.: [redacted]

SIGNATURE PAGE

CLINICAL SAFETY EVALUATION

REPEATED INSULT PATCH TEST

[redacted]

[redacted]

January 20, 2000
Date

[redacted]

Date

[redacted]

1/19/00
Date

[redacted]

QUALITY ASSURANCE STATEMENT

This study was conducted in accordance with the intent and purpose of Good Clinical Practice regulations described in CFR Title 21, Parts 50, 56 and 312 and/or the Declaration of Helsinki, as appropriate.

For purposes of this clinical study:

X	Informed Consent was obtained.
_____	Informed Consent was not obtained.
X	An IRB review was not required.
_____	An IRB review was conducted and approval to conduct the proposed clinical research was granted.

This study report has been reviewed to assure that it correctly describes the methods of testing and that the reported results accurately reflect the data obtained during the clinical study ([redacted] Panel No.: [redacted]; [redacted] Entry No.: [redacted]).

[redacted]

19 Jan 2000
Date

[redacted]

[redacted] Panel No.:
Entry No.: [redacted]

TABLE OF CONTENTS

[redacted]

[redacted]Panel No.:
Entry No.: [redacted]

CLINICAL SAFETY EVALUATION

REPEATED INSULT PATCH TEST

[redacted]

1.0 OBJECTIVE

The objective of this study was to determine the irritation and/or sensitization potential of the test article after repeated application under occlusive patch test conditions to the skin of human subjects (exclusive panel).

2.0 SPONSOR

[redacted]

2.1 Sponsor Representatives

[redacted]

3.0 CLINICAL TESTING FACILITY

The study was conducted by:

[redacted]

4.0 CLINICAL INVESTIGATORS

[redacted]

5.0 STUDY DATES

Study initiation: November 22, 1999

Final evaluation: January 3, 2000

[redacted]

6.0 ETHICS

6.1 Ethical Conduct of the Study

This study was conducted in accordance with the intent and purpose of Good Clinical Practice regulations described in Title 21 of the U.S. Code of Federal Regulations (CFR), the Declaration of Helsinki and/or [redacted] Standard Operating Procedures.

6.2 Subject Information and Consent

This study was conducted in compliance with CFR Title 21, Part 50 (Informed Consent of Human Subjects). Informed Consent was obtained from each subject in the study and documented in writing before participation in the study. A copy of the Informed Consent was provided to each subject.

7.0 TEST MATERIAL

The test article used in this study was provided by:

[redacted]

It was received on November 8, 1999 and identified as follows:

[redacted] Entry No.	Test Article I.D.	Physical Description
[redacted]	[redacted]	[redacted]

8.0 TEST SUBJECTS

A total of 62 subjects, 16 males and 46 females ranging in age from 19 to 67 years, were empaneled for this test.

The subjects chosen were dependable and able to read and understand instructions. The subjects did not exhibit any physical or dermatological condition that would have precluded application of the test article or determination of potential effects of the test article.

[redacted]

9.0 TEST PROCEDURE

The 9 Repeated Insult (occlusive) Patch Test (9-RIPT) was conducted as follows:

9.1 Induction Phase

A sufficient amount of the test article (an amount to adequately cover the surface of the patch unit-approximately 0.1 g - 0.15 g) was placed onto a Parke-Davis Readi-Bandage® occlusive patch and was applied to the back of each subject between the scapulae and waist, adjacent to the spinal mid-line. This procedure was repeated every Monday, Wednesday and Friday until nine (9) applications of the test article had been made.

The subjects were instructed to remove the patch 24 hours after application. Twenty-four hour rest periods followed the Tuesday and Thursday removals and 48-hour rest periods followed each Saturday removal. Subjects returned to the Testing Facility and the site was scored by a trained examiner just prior to the next patch application.

If a subject developed a positive reaction of a 2-level erythema or greater during the Induction phase or if, at the discretion of the Study Director, the skin response warranted a change in site, the patch was applied to a previously unpatched, adjacent site for the next application. If a 2-level reaction or greater occurred at the new site, no further applications were made. However, any reactive subjects were subsequently Challenge patch tested.

9.2 Challenge Phase

After a rest period of approximately 2 weeks (no applications of the test article), the Challenge patch was applied to a previously unpatched (virgin) test site. The site was scored 24 and 72 hours after application. All subjects were instructed to report any delayed skin reactivity that occurred after the final Challenge patch reading. When warranted, selected test subjects were called back to the Clinic for additional examinations and scoring to determine possible increases or decreases in Challenge patch reactivity.

Dermal responses for both the Induction and Challenge phases of the study were scored according to the following 6-point scale:

0 = No evidence of any effect
+ = Barely perceptible (Minimal, faint, uniform or spotty erythema)
1 = Mild (Pink, uniform erythema covering most of the contact site)
2 = Moderate (Pink-red erythema uniform in the entire contact site)
3 = Marked (Bright red erythema with/without petechiae or papules)
4 = Severe (Deep red erythema with/without vesiculation or weeping)

All other observed dermal sequelae (eg, edema, dryness, hypo- or hyperpigmentation) were appropriately recorded on the data sheet and described as mild, moderate or severe.

[redacted]

10.0 RESULTS AND DISCUSSION

(See Table 1 for Individual Scores)

Fifty-three (53/62) subjects satisfactorily completed the test procedure on Test Article: [redacted] Eight (8/62) subjects discontinued for personal reasons unrelated to the conduct of the study. One (1/62) panelist (Subject No. 37) discontinued due to violation of the Protocol; the test subject was concurrently testing at another facility. Discontinued panelist data are shown up to the point of discontinuation, but are not used in the Conclusions section of this final report.

There was no skin reactivity observed at any time during the course of the study.

11.0 CONCLUSIONS

Under the conditions of a repeated insult (occlusive) patch test procedure, Test Article: [redacted] did not induce skin irritation nor show any evidence of induced allergic contact dermatitis in human subjects.

[redacted]

[redacted] Panel No.:
Entry No.: [redacted]

TABLE 1

INDIVIDUAL SCORES

REPEATED INSULT PATCH TEST - OCCLUSIVE

Test Article: [redacted]

Subj. No.	Induction Evaluation Number 1	2	3	4	5	6	7	8	9	Challenge Virgin Site 24hr	72hr
1	0	0	0	0	0	0	0	0	0	0	0
2	0	0	0	0	0	0	0	0	0	0	0
3	0	0	0	0	0	0	0	0	0	0	0
4	0	0	0	0	0	0	0	0	0	0	0
5	0	0	0	0	0	0	0	0	0	0	0
6	0	0	0	0	0	0	0	0	0	0	0
7	0	0	0	Discontinued							
8	0	0	0	0	0	0	0	0	0	0	0
9	0	0	0	0	0	0	0	0	0	0	0
10	0	0	0	0	0	0	0	0	0	0	0
11	0	0	0	0	0	0	0	0	0	0	0
12	0	0	0	0	0	0	0	0	0	0	0
13	0	0	0	0	0	0	0	0	0	0	0
14	0	0	0	0	0	0	0	0	0	0	0
15	0	0	0	0	0	0	0	0	0	0	0
16	0	0	0	0	0	0	0	0	0	0	0
17	0	0	0	0	0	0	0	0	0	0	0
18	0	Discontinued									
19	0	0	0	0	0	0	0	0	0	0	0
20	0	0	0	0	0	0	0	0	0	0	0
21	Discontinued										
22	0	0	0	0	0	0	0	0	0	0	0
23	0	0	0	0	0	0	0	0	0	0	0
24	0	0	0	0	0	0	0	0	0	0	0
25	0	0	0	0	0	0	0	0	0	0	0
26	0	0	0	0	0	0	0	0	0	0	0
27	0	0	0	0	0	0	0	0	0	0	0
28	0	0	0	0	0	0	0	0	0	0	0
29	0	0	0	0	0	0	0	0	0	0	0
30	0	0	0	0	0	0	0	0	0	0	0

Scale: 0 = No evidence of any effect
+ = Barely perceptible (Minimal, faint, uniform or spotty erythema)
1 = Mild (Pink, uniform erythema covering most of the contact site)
2 = Moderate (Pink-red erythema uniform in the entire contact site)
3 = Marked (Bright red erythema with/without petechiae or papules)
4 = Severe (Deep red erythema with/without vesiculation or weeping)

[redacted]

[redacted] Panel No.:
Entry No.: [redacted]

TABLE 1 (CONT'D)

INDIVIDUAL SCORES

REPEATED INSULT PATCH TEST - OCCLUSIVE

Test Article: [redacted]

Subj. No.	Induction Evaluation Number 1	2	3	4	5	6	7	8	9	Challenge Virgin Site 24hr	72hr
31	0	0	0	0	0	0	0	0	0	0	0
32	0	0	0	0	0	0	0	0	0	0	0
33	0	0	0	0	0	0	0	0	0	0	0
34	0	0	0	0	0	0	0	0	0	0	0
35	0	0	0	0	0	0	0	0	0	0	0
36	0	0	0	0	0	0	0	0	0	0	0
37	0	0	0	0	Discontinued						
38	0	0	0	0	0	0	0	0	0	0	0
39	0	0	0	0	0	0	0	0	0	0	0
40	Discontinued										
41	0	0	0	0	0	0	0	0	0	0	0
42	0	0	0	0	0	0	0	0	0	0	0
43	0	0	0	0	0	0	0	0	0	0	0
44	0	0	0	0	0	0	0	0	0	0	0
45	0	0	0	0	0	0	0	0	0	0	0
46	0	0	0	0	0	0	0	0	0	0	0
47	Discontinued										
48	0	0	0	0	0	0	0	0	0	0	0
49	0	0	0	0	0	0	0	0	0	0	0
50	0	0	0	0	0	0	0	0	0	0	0
51	0	0	0	0	0	0	0	0	0	0	0
52	0	0	0	0	0	0	0	0	0	Discontinued	
53	0	0	0	0	0	0	0	0	0	0	0
54	0	0	0	0	0	0	0	0	0	0	0
55	0	Discontinued									
56	0	0	0	0	0	0	0	0	0	0	0
57	0	0	0	0	0	0	0	0	0	0	0
58	0	0	0	0	0	0	0	0	0	0	0
59	0	0	0	0	0	0	0	0	0	0	0
60	Discontinued										
61	0	0	0	0	0	0	0	0	0	0	0
62	0	0	0	0	0	0	0	0	0	0	0

Scale: 0 = No evidence of any effect
+ = Barely perceptible (Minimal, faint, uniform or spotty erythema)
1 = Mild (Pink, uniform erythema covering most of the contact site)
2 = Moderate (Pink-red erythema uniform in the entire contact site)
3 = Marked (Bright red erythema with/without petechiae or papules)
4 = Severe (Deep red erythema with/without vesiculation or weeping)

[redacted]

[redacted] Panel No.:
Entry No.: [redacted]

TABLE 2

SUBJECT DEMOGRAPHICS

Test Article: [redacted]

Subj. No.	Initials	Sex	Age	Race	Subj. No.	Initials	Sex	Age	Race
1	SED	F	38	CE	32	LAA	F	38	CE
2	C-B	F	66	CE	33	M-S	F	44	CE
3	EBH	M	58	CE	34	JAW	F	33	CE
4	RBH	F	56	CE	35	T-G	F	31	CE
5	JLE	F	42	CE	36	JMM	F	45	CE
6	MAR	F	52	CE	37	A-R	F	39	CE
7	AJS	M	41	CE	38	DMC	F	25	CE
8	C-D	F	50	CE	39	AMS	F	57	CE
9	MDB	F	56	BA	40	L-R	F	34	BA
10	JBG	F	42	CE	41	MJM	M	35	CE
11	WEA	M	64	CE	42	L-D	M	37	CE
12	JAF	F	54	CE	43	DRS	F	55	O
13	RAM	M	49	CE	44	F-B	M	37	O
14	E-M	F	47	CE	45	MJK	M	52	CE
15	E-C	F	64	CE	46	PYZ	M	20	AS
16	M-M	F	39	CE	47	GES	F	42	CE
17	P-H	F	40	CE	48	JPC	M	43	CE
18	M-D	F	37	AS	49	JAS	F	54	CE
19	LWT	F	38	CE	50	PMB	F	63	CE
20	LCF	F	34	CE	51	J-M	F	36	CE
21	D-H	F	38	BA	52	DAR	F	47	CE
22	DJM	F	39	CE	53	JCS	F	64	CE
23	GAB	M	65	CE	54	BAA	F	54	CE
24	SAB	F	62	CE	55	MKG	F	19	BA
25	DAR	M	50	BA	56	BJZ	F	67	CE
26	CMP	F	61	BA	57	D-S	F	37	CE
27	YLC	F	62	CE	58	DJH	F	45	BA
28	KMA	F	39	CE	59	G-V	M	46	CE
29	R-C	M	57	BA	60	HOV	F	36	CE
30	J-C	F	49	BA	61	BJB	F	47	BA
31	JRT	M	50	CE	62	W-J	M	65	BH

AS = Asian or Pacific Islander
BA = Black (Non-Hispanic/African American)
CE = White (Non-Hispanic)
O = Other

Shaded area = Discontinued subject

[redacted]

FINAL REPORT

CLINICAL SAFETY EVALUATION

REPEATED INSULT PATCH TEST

[redacted]

Product contains 0.005% Salvia Officinalis (Sage) Leaf Extract (1% dilution tested)

Sponsor

[redacted]

Sponsor Representative

[redacted]
Divisional Vice President of Research

Clinical Testing Facility

[redacted]

Sponsor Code: [redacted]

Date of Final Report

7-24-17

[redacted]

[redacted]

SIGNATURE PAGE

CLINICAL SAFETY EVALUATION

REPEATED INSULT PATCH TEST

[redacted]

[redacted]
Board-Certified Dermatologist
Medical Investigator

7/20/17
Date

[redacted]

QUALITY ASSURANCE STATEMENT

This study [redacted]) was conducted in accordance with the intent and purpose of Good Clinical Practice regulations described in 21 CFR Part 50 (Protection of Human Subjects – Informed Consent) and the Standard Operating Procedures of [redacted]

For purposes of this clinical study:

_X_	Informed Consent was obtained.
____	Informed Consent was not obtained.
_X_	An IRB review was not required.
____	An IRB review was conducted and approval to conduct the proposed clinical research was granted.

To assure compliance with the study protocol, the Quality Assurance Unit completed an audit of the applicable study records and report. This report is considered a true and accurate reflection of the testing methods and source data.

[redacted]
Manager, Quality Assurance

21 July 2017
Date

[redacted]

[redacted]

TABLE OF CONTENTS

[redacted]

[redacted]

CLINICAL SAFETY EVALUATION

REPEATED INSULT PATCH TEST

[redacted]

1.0 OBJECTIVE

The objective of this study was to determine the irritation and/or sensitization potential of the test article after repeated application under occlusive patch test conditions to the skin of human subjects (non-exclusive panel), 25% of whom were to have self-perceived sensitive skin.

2.0 SPONSOR

[redacted]

2.1 Sponsor Representative

[redacted]
Divisional Vice President of Research

3.0 CLINICAL TESTING FACILITY

The study was conducted by:

[redacted]

4.0 CLINICAL INVESTIGATORS

Study Director: [redacted], BA
Principal Investigator: [redacted] PhD, DABT, BCFE
Medical Investigator: [redacted] MD, Board-Certified Dermatologist

5.0 STUDY DATES

Study initiation: May 31, 2017

Final evaluation: July 14, 2017

[redacted]

[redacted]

6.0 ETHICS

6.1 Ethical Conduct of the Study

This study was conducted in accordance with the intent and purpose of Good Clinical Practice regulations described in Title 21 of the U.S. Code of Federal Regulations (CFR), the Declaration of Helsinki and/or [redacted] Standard Operating Procedures.

6.2 Subject Information and Consent

This study was conducted in compliance with CFR Title 21, Part 50 (Informed Consent of Human Subjects). Informed Consent was obtained from each subject in the study and documented in writing before participation in the study. A copy of the Informed Consent was provided to each subject.

7.0 TEST MATERIAL

The test article used in this study was provided by:

[redacted]

It was received on May 26, 2017 and identified as follows:

[redacted]	Test Article ID	Description
[redacted]	[redacted]	Peach Cream with Granules*

*The test article was prepared as a 1% aqueous (distilled water) solution and was shaken well prior to application to the patch.

8.0 TEST SUBJECTS

At least 50 male and female subjects ranging in age from 18 to 79 years, 25% of whom were to have self-perceived sensitive skin, were to be empanelled for this test.

The subjects chosen were to be dependable and able to read and understand instructions. The subjects were not to exhibit any physical or dermatologic condition that would have precluded application of the test article or determination of potential effects of the test article.

[redacted]

9.0 TEST PROCEDURE

The 9 Repeated Insult (occlusive) Patch Test (9-RIPT)[1] was conducted as follows:

9.1 Induction Phase

A sufficient amount of the test article (approximately 0.2 mL) was placed onto a Parke-Davis Readi-Bandage® occlusive patch (approximately 0.05 mL/cm^2 of test material), which was applied to the back of each subject between the scapulae and waist, adjacent to the spinal mid-line. This procedure was performed by a trained technician/examiner and repeated every Monday, Wednesday and Friday until 9 applications of the test article had been made.

The subjects were instructed to remove the patch 24 hours after application. Twenty-four hour rest periods followed the Tuesday and Thursday removals and 48-hour rest periods followed each Saturday removal. Subjects returned to the Testing Facility and the site was scored by a trained examiner just prior to the next patch application.

If a subject developed a positive reaction of a level 2 erythema or greater during the Induction phase or if, at the discretion of the Study Director, the skin response warranted a change in site, the patch was applied to a previously unpatched, adjacent site for the next application. If a level 2 reaction or greater occurred at the new site, no further applications were made. However, any reactive subjects were subsequently Challenge patch tested.

9.2 Challenge Phase

After a rest period of approximately 2 weeks (no applications of the test article), the Challenge patch was applied to a previously unpatched (virgin) test site. The site was scored 24 and 72 hours after application. All subjects were instructed to report any delayed skin reactivity that occurred after the final Challenge patch reading. When warranted, selected test subjects were called back to the Clinic for additional examinations and scoring to determine possible increases or decreases in Challenge patch reactivity.

Dermal responses for both the Induction and Challenge phases of the study were scored according to the following 6-point scale:

0 = No evidence of any effect
+ = Barely perceptible (Minimal, faint, uniform or spotty erythema)
1 = Mild (Pink, uniform erythema covering most of the contact site)
2 = Moderate (Pink-red erythema uniform in the entire contact site)
3 = Marked (Bright red erythema with/without petechiae or papules)
4 = Severe (Deep red erythema with/without vesiculation or weeping)

All other observed dermal sequelae (eg, edema, dryness, hypo- or hyperpigmentation) were appropriately recorded on the data sheet and described as mild, moderate or severe.

[1] Marzulli FN, Maibach HI. (1976) Contact allergy: predictive testing in man. *Contact Dermatitis*. 2, 1-17.
[redacted]

9.0 TEST PROCEDURE (CONT'D)

9.3 Data Interpretation

Edema, vesicles, papules and/or erythema that persist or increase in intensity either during the Induction and/or Challenge phase may be indicative of allergic contact dermatitis. Allergic responses normally do not resolve or improve markedly at 72-96 hours.

Exceptions to typical skin reactions may occur. These may include, but not be limited to, symptoms of allergic contact sensitivity early in the Induction period to one or more test products. When this occurs in one subject, such a reaction usually suggests either an idiosyncratic response or that the subject had a pre-exposure/sensitization to the test material or component(s) of the test material or a cross-reactivity with a similar product/component. Data for such reactions will be included in the study report but will not be included in the final study analysis/conclusion of sensitization.

10.0 RESULTS AND DISCUSSION

(See Table 1 for Individual Scores)

A total of 58 subjects (19 males and 39 females ranging in age from 18 to 75 years, 15 of whom had self-perceived sensitive skin) were empanelled for the test procedure. Fifty-three (53/58) subjects satisfactorily completed the test procedure on Test Article: [redacted] (@ 1% aqueous). Five (5/58) subjects discontinued for personal reasons unrelated to the conduct of the study. Discontinued subject data are shown up to the point of discontinuation, but are not used in the Conclusions section of this final report.

Induction Phase Summary

Test Article	Induction Scores (Number of Responses)						Evidence of Irritation
	0.5	1	2	3	4	Other	
LM Face Polish Reformulation Formula#: 00N14614-2 (@ 1% aqueous)	0	0	0	0	0	0	No

Challenge Phase Summary

Test Article	Challenge Scores (Number of Responses)						Evidence of Sensitization
	0.5	1	2	3	4	Other	
LM Face Polish Reformulation Formula#: 00N14614-2 (@ 1% aqueous)	0	0	0	0	0	0	No

There was no skin reactivity observed at any time during the course of the study.

11.0 CONCLUSIONS

Under the conditions of a repeated insult (occlusive) patch test procedure conducted in 53 subjects (28% of whom had self-perceived sensitive skin), Test Article: [redacted] (@ 1% aqueous) was "Dermatologist-Tested" and was not associated with skin irritation or allergic contact dermatitis in human subjects.

TABLE 1

INDIVIDUAL SCORES

REPEATED INSULT PATCH TEST - OCCLUSIVE

Test Article: [redacted]
(@ 1% aqueous)

Subj. No.	Induction Evaluation Number									Challenge Virgin Site	
	1	2	3	4	5	6	7	8	9	24hr	72hr
1	0	0	0	0	0	0	0	0	0	0	0
2	Discontinued										
3	0	0	0	0	0	0	0	0	0	0	0
4	0	0	0	0	0	0	0	0	0	0	0
5	0	0	0	0	0	0	0	0	0	0	0
6	0	0	0	0	0	0	0	0	0	0	0
7	0	0	0	0	0	0	0	0	0	0	0
8	0	0	0	0	0	0	0	0	0	0	0
9	0	0	0	0	0	0	0	0	0	0	0
10	0	0	0	0	0	0	0	0	0	0	0
11	0	0	0	0	0	0	0	0	0	0	0
12	0	0	0	0	0	0	0	0	0	0	0
13	0	0	0	0	0	0	0	0	0	0	0
14	0	0	0	0	0	0	0	0	0	0	0
15	0	0	0	0	0	0	0	0	0	0	0
16	0	0	0	0	0	0	0	0	0	0	0
17	0	0	0	0	0	0	0	0	0	0	0
18	0	0	0	0	0	0	0	0	0	0	0
19	0	0	0	0	0	0	0	0	0	0	0
20	0	0	0	0	0	0	0	0	0	0	0
21	0	0	0	0	0	0	0	0	0	0	0
22	0	0	0	0	0	0	0	0	0	0	0
23	0	0	0	0	0	0	0	0	0	0	0
24	0	0	0	0	0	0	0	0	0	0	0
25	0	0	0	0	0	0	0	0	0	0	0
26	0	0	0	0	0	0	0	0	0	0	0
27	0	0	0	0	0	0	0	0	0	0	0
28	0	0	0	0	0	0	0	0	0	0	0
29	0	0	0	0	0	0	0	0	0	0	0
30	0	0	0	0	0	0	0	0	0	0	0

Scale:0 = No evidence of any effect
+ = Barely perceptible (Minimal, faint, uniform or spotty erythema)
1 = Mild (Pink, uniform erythema covering most of the contact site)
2 = Moderate (Pink-red erythema uniform in the entire contact site)
3 = Marked (Bright red erythema with/without petechiae or papules)
4 = Severe (Deep red erythema with/without vesiculation or weeping)

TABLE 1 (CONT'D)

INDIVIDUAL SCORES

REPEATED INSULT PATCH TEST - OCCLUSIVE

Test Article: [redacted]
(@ 1% aqueous)

Subj. No.	Induction Evaluation Number									Challenge Virgin Site	
	1	2	3	4	5	6	7	8	9	24hr	72hr
31	0	0	0	0	0	0	0	0	0	0	0
32	0	0	0	0	0	0	0	0	0	0	0
33	0	0	0	0	0	0	0	0	0	0	0
34	0	0	0	0	0	0	0	0	0	0	0
35	0	0	0	0	0	0	0	0	0	0	0
36	0	0	0	0	0	0	0	0	0	0	0
37	0	0	0	0	0	0	0	0	0	0	0
38	0	0	0	0	0	0	0	0	0	0	0
39	0	0	0	0	0	0	0	0	0	0	0
40	0	0	0	0	0	0	0	0	0	0	0
41	0	0	0	0	0	0	0	0	0	0	0
42	0	0	0	0	0	0	0	0	0	0	0
43	0	0	0	0	0	0	0	0	0	0	0
44	0	0	0	0	0	0	0	0	0	Discontinued	
45	0	0	0	0	0	0	0	0	0	0	0
46	0	0	0	0	0	0	0	0	0	0	0
47	0	0	0	0	0	0	0	0	0	0	0
48	0	0	0	0	0	0	0	0	0	0	0
49	0	0	0	0	0	0	0	0	0	0	0
50	0	0	0	0	0	0	0	0	0	Discontinued	
51	0	0	0	0	0	0	0	0	0	0	0
52	0	0	Discontinued								
53	0	0	0	0	0	0	0	0	0	0	0
54	0	0	0	0	0	0	0	0	0	0	0
55	0	0	0	0	0	0	0	0	0	0	0
56	0	0	0	Discontinued							
57	0	0	0	0	0	0	0	0	0	0	0
58	0	0	0	0	0	0	0	0	0	0	0

Scale:0 = No evidence of any effect
+ = Barely perceptible (Minimal, faint, uniform or spotty erythema)
1 = Mild (Pink, uniform erythema covering most of the contact site)
2 = Moderate (Pink-red erythema uniform in the entire contact site)
3 = Marked (Bright red erythema with/without petechiae or papules)
4 = Severe (Deep red erythema with/without vesiculation or weeping)

2021 VCRP Frequency of Use Data – *Salvia officinalis* (Sage)- Derived Ingredients

INGREDIENT NAME	CATEGORY CODE	CATEGORY DESCRIPTION	CPIS COUNT
Salvia Officinalis (Sage) Extract Total Uses: 66			
Salvia Officinalis (Sage) Extract	05A	Hair Conditioner	5
Salvia Officinalis (Sage) Extract	05F	Shampoos (non-coloring)	10
Salvia Officinalis (Sage) Extract	05G	Tonics, Dressings, and Other Hair Grooming Aids	10
Salvia Officinalis (Sage) Extract	05I	Other Hair Preparations	5
Salvia Officinalis (Sage) Extract	06H	Other Hair Coloring Preparation	1
Salvia Officinalis (Sage) Extract	09A	Dentifrices	3
Salvia Officinalis (Sage) Extract	10A	Bath Soaps and Detergents	1
Salvia Officinalis (Sage) Extract	10B	Deodorants (underarm)	1
Salvia Officinalis (Sage) Extract	12A	Cleansing	2
Salvia Officinalis (Sage) Extract	12C	Face and Neck (exc shave)	11
Salvia Officinalis (Sage) Extract	12D	Body and Hand (exc shave)	6
Salvia Officinalis (Sage) Extract	12F	Moisturizing	3
Salvia Officinalis (Sage) Extract	12H	Paste Masks (mud packs)	3
Salvia Officinalis (Sage) Extract	12I	Skin Fresheners	2
Salvia Officinalis (Sage) Extract	12J	Other Skin Care Preps	3
Salvia Officinalis (Sage) Leaf Total Uses: 1			
Salvia Officinalis (Sage) Leaf	12J	Other Skin Care Preps	1
Salvia Officinalis (Sage) Leaf Extract Total Uses: 213			
Salvia Officinalis (Sage) Leaf Extract	02A	Bath Oils, Tablets, and Salts	2
Salvia Officinalis (Sage) Leaf Extract	02D	Other Bath Preparations	1
Salvia Officinalis (Sage) Leaf Extract	03D	Eye Lotion	4
Salvia Officinalis (Sage) Leaf Extract	05A	Hair Conditioner	17
Salvia Officinalis (Sage) Leaf Extract	05B	Hair Spray (aerosol fixatives)	1
Salvia Officinalis (Sage) Leaf Extract	05F	Shampoos (non-coloring)	27
Salvia Officinalis (Sage) Leaf Extract	05G	Tonics, Dressings, and Other Hair Grooming Aids	10
Salvia Officinalis (Sage) Leaf Extract	05I	Other Hair Preparations	6
Salvia Officinalis (Sage) Leaf Extract	06C	Hair Rinses (coloring)	7
Salvia Officinalis (Sage) Leaf Extract	06D	Hair Shampoos (coloring)	9
Salvia Officinalis (Sage) Leaf Extract	06G	Hair Bleaches	1

2021 VCRP Frequency of Use Data – *Salvia officinalis* (Sage)- Derived Ingredients

Salvia Officinalis (Sage) Leaf Extract	07D	Leg and Body Paints	2
Salvia Officinalis (Sage) Leaf Extract	07F	Makeup Bases	1
Salvia Officinalis (Sage) Leaf Extract	09A	Dentifrices	3
Salvia Officinalis (Sage) Leaf Extract	09B	Mouthwashes and Breath Fresheners	1
Salvia Officinalis (Sage) Leaf Extract	10A	Bath Soaps and Detergents	26
Salvia Officinalis (Sage) Leaf Extract	10B	Deodorants (underarm)	4
Salvia Officinalis (Sage) Leaf Extract	10E	Other Personal Cleanliness Products	3
Salvia Officinalis (Sage) Leaf Extract	11A	Aftershave Lotion	1
Salvia Officinalis (Sage) Leaf Extract	11E	Shaving Cream	1
Salvia Officinalis (Sage) Leaf Extract	12A	Cleansing	17
Salvia Officinalis (Sage) Leaf Extract	12C	Face and Neck (exc shave)	19
Salvia Officinalis (Sage) Leaf Extract	12D	Body and Hand (exc shave)	7
Salvia Officinalis (Sage) Leaf Extract	12F	Moisturizing	27
Salvia Officinalis (Sage) Leaf Extract	12G	Night	1
Salvia Officinalis (Sage) Leaf Extract	12H	Paste Masks (mud packs)	4
Salvia Officinalis (Sage) Leaf Extract	12I	Skin Fresheners	4
Salvia Officinalis (Sage) Leaf Extract	12J	Other Skin Care Preps	7
Salvia Officinalis (Sage) Leaf Oil			
Total Uses: 2			
Salvia Officinalis (Sage) Leaf Oil	02A	Bath Oils, Tablets, and Salts	1
Salvia Officinalis (Sage) Leaf Oil	09A	Dentifrices	1
Salvia Officinalis (Sage) Leaf Water			
Total Uses: 3			
Salvia Officinalis (Sage) Leaf Water	10B	Deodorants (underarm)	1
Salvia Officinalis (Sage) Leaf Water	12A	Cleansing	1
Salvia Officinalis (Sage) Leaf Water	12I	Skin Fresheners	1
Salvia Officinalis (Sage) Oil			
Total Uses: 87			

2021 VCRP Frequency of Use Data – *Salvia officinalis* (Sage)- Derived Ingredients

Salvia Officinalis (Sage) Oil	02A	Bath Oils, Tablets, and Salts	2
Salvia Officinalis (Sage) Oil	02B	Bubble Baths	1
Salvia Officinalis (Sage) Oil	02D	Other Bath Preparations	3
Salvia Officinalis (Sage) Oil	03D	Eye Lotion	1
Salvia Officinalis (Sage) Oil	05B	Hair Spray (aerosol fixatives)	1
Salvia Officinalis (Sage) Oil	05F	Shampoos (non-coloring)	2
Salvia Officinalis (Sage) Oil	05G	Tonics, Dressings, and Other Hair Grooming Aids	6
Salvia Officinalis (Sage) Oil	05I	Other Hair Preparations	2
Salvia Officinalis (Sage) Oil	07D	Leg and Body Paints	2
Salvia Officinalis (Sage) Oil	09A	Dentifrices	1
Salvia Officinalis (Sage) Oil	09C	Other Oral Hygiene Products	1
Salvia Officinalis (Sage) Oil	10A	Bath Soaps and Detergents	2
Salvia Officinalis (Sage) Oil	10B	Deodorants (underarm)	2
Salvia Officinalis (Sage) Oil	11B	Beard Softeners	2
Salvia Officinalis (Sage) Oil	11E	Shaving Cream	2
Salvia Officinalis (Sage) Oil	11G	Other Shaving Preparation Products	1
Salvia Officinalis (Sage) Oil	12A	Cleansing	7
Salvia Officinalis (Sage) Oil	12C	Face and Neck (exc shave)	6
Salvia Officinalis (Sage) Oil	12D	Body and Hand (exc shave)	5
Salvia Officinalis (Sage) Oil	12F	Moisturizing	15
Salvia Officinalis (Sage) Oil	12G	Night	1
Salvia Officinalis (Sage) Oil	12H	Paste Masks (mud packs)	9
Salvia Officinalis (Sage) Oil	12J	Other Skin Care Preps	13
Salvia Officinalis (Sage) Water			
Total Uses: 1			
Salvia Officinalis (Sage) Water	12C	Face and Neck (exc shave)	1